

+

+

1

1

Attorney Docket No.	BTI-39 CIP
First Inventor or Application Identifier	Robert Granados
Title	A Novel Invertebrate Intestinal Mucin... Methods
Express Mail Label No.	EL304701302

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
 (* Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 60]
 (preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 4]
 (See Box 5 below)
4. Oath or Declaration [Total Pages 1]
- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
 (for continuation/divisional with Box 17 completed)
 (Note Box 5 below)
- i. ☐ ~~DELETION OF INVENTOR(S)~~
 Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☒ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☒ Statement verifying identity of above copies

8. ☐ Assignment Papers (cover sheet & document(s))

9. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)

10. ☐ English Translation Document (if applicable)

11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

12. ☐ Preliminary Amendment

13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. ☒ * Small Entity Statement(s) ☐ Statement filed in prior application,
(PTO/SB/03-12) Status still proper and desired

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Other:

* NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:
- | | | | |
|---------------------------------------|-------------------------------------|--|---------------------------------------|
| <input type="checkbox"/> Continuation | <input type="checkbox"/> Divisional | <input checked="" type="checkbox"/> Continuation-in-part (CIP) | of prior application No: 09 / 103,429 |
|---------------------------------------|-------------------------------------|--|---------------------------------------|

Prior application information: Examiner R. Schnizer, R. Group / Art Unit: 1632

☒ Customer Number or Bar Code Label **020808** or ☐ Correspondence address below
(Insert Customer No. or Attach bar code label here)

Name _____

Address

City

Country

State

Telephone

Zip Code _____

Fax

Name (Print/Type)

Christopher A. Michaels

Registration No. (Attorney/Agent)

34,390

Signature _____

Date _____

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Applicant or Patentee: Robert R. Granados and Ping Wang

Serial or Patent No.: _____ Attorney Docket No.: BTI-39 CIP

Filed or Issued: April 19, 1999

Title: "A NOVEL INVERTEBRATE INTESTINAL MUCIN cDNA AND RELATED PRODUCTS AND METHODS"

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d) - NONPROFIT ORGANIZATION)

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION Boyce Thompson Institute for Plant Research, Inc.

ADDRESS OF ORGANIZATION Tower Road, Ithaca, New York 14850

TYPE OF ORGANIZATION

☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION

☒ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))

☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES

OF AMERICA

(NAME OF STATE _____)

(CITATION OF STATUTE _____)

☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA

☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA

(NAME OF STATE _____)

(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled A NOVEL INVERTEBRATE INTESTINAL

MUCIN cDNA AND RELATED PRODUCTS AND METHODS

by Inventor(s) Robert R. Granados and Ping Wang

☒ the specification filed herewith

☐ application serial number _____, filed _____

☐ patent number _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). * NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities.

NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING ----- Joyce Frank

TITLE OF PERSON SIGNING Vice President of Operations
Boyce Thompson Institute for Plant Research, Inc.

ADDRESS OF PERSON SIGNING -- Tower Road, Ithaca, New York 14850

SIGNATURE



DATE

4-19-99

A NOVEL INVERTEBRATE INTESTINAL MUCIN cDNA AND RELATED PRODUCTS AND METHODS

REFERENCE TO RELATED APPLICATIONS

5 This is a continuation-in-part application of co-pending parent patent application serial number 09/103,429, filed June 24, 1998. The aforementioned application(s) are hereby incorporated herein by reference.

FIELD OF THE INVENTION

10 The invention pertains to the field of proteins associated with the peritrophic membranes of insects. More particularly, the invention pertains to a novel invertebrate intestinal mucin cDNA and related products and methods.

BACKGROUND OF THE INVENTION

15 Vertebrate epithelial organs are covered, throughout the body, with a mucus lining, which serves as a selective physical barrier between extracellular contents and the epithelial cell surface. The mucus lining, especially in the gastrointestinal tract, is highly resistant to various digestive enzymes and provides protection and lubrication for the underlying cells. The protective functions of the mucosal layer are largely
20 dependent upon heavily glycosylated proteins known as mucins. Mucins play an active role in preventing bacterial, viral, and other pathogens from interacting with vertebrate intestinal epithelia.

 Mucins are highly *O*-glycosylated proteins. Carbohydrate moieties on mucins commonly account for more than 50% of the protein by weight. The biochemistry and
25 molecular biology of mucins from vertebrates has been broadly investigated, with

human epithelial mucins being the most extensively studied. Several mucins from humans and other vertebrates have been completely or partially sequenced, and this has contributed to a greater understanding of their structure and function. Full cDNA sequences for human mucin MUC1, MUC2, and MUC7, have been obtained. In addition, mucins from other vertebrates, including mouse MUC-1, rat ascites sialoglycoprotein-1, canine tracheobronchial mucin, bovine submaxillary mucin-like protein, and frog IIM-A.1, have also been fully sequenced by cDNA cloning.

Studies on invertebrate mucins are very limited in comparison with vertebrate mucins. *Drosophila melanogaster* "glue proteins" from salivary glands have structural characteristics of mucin-like proteins. These "glue protein" have been sequenced but their function has not been fully determined. Mucin-like proteins have also been reported in protozoans. A secretory mucin involved in maintaining the cohesiveness of a clutch of a squid egg-mass formation was identified from that animal's nidamental gland. A glycoprotein from *Drosophila melanogaster* cultured cells was reported to be a mucin-like protein. Recently, a membrane-associated mucin from the hemocytes of *Drosophila melanogaster* was identified, and a cDNA for the mucin was subsequently cloned. However, to date, there have been no reports on mucins identified from invertebrate digestive tracts.

Part of the reason for this may be that insects do not possess a mucus layer lining the digestive tract and/or other epithelial cells, as do vertebrates. The digestive tract in insects is commonly lined with an invertebrate-unique structure, the peritrophic membrane (PM). PMs are non-cellular matrices composed primarily of chitin, protein, and glycoproteins. PMs demonstrate a protective function similar to the mucus layer in vertebrates (e.g. a selective barrier protecting the digestive tract from physical damages and microbial infections).

Although there are few studies on the interaction between microbial pathogens and PMs, these structures are proposed to serve as a physical barrier to invasion or infection by pathogenic microorganisms. The chitin component of PMs is normally present as a network of chitin fibrils in which proteins and glycoproteins are present.

The chitin can be a potential target substrate for intestinal pathogens. This was

demonstrated through the degradation of chitin in the PM by a pathogen-encoded chitinase allowing an avian malaria parasite to overcome its mosquito vector intestinal PM barrier and infect the vector itself.

Proteins are the major PM component; however, their functions in the PM are unknown. Studies on the PM proteins are limited to analyses of the amino acid composition of total PM proteins and PM protein profiles as determined by electrophoresis. The only PM protein characterized to date, peritrophin-44, was isolated from *Lucille cuprina* larvae, but its biological function is not fully understood. To date, studies on the interaction of PM proteins with microbial pathogens are limited to the effect of a baculovirus enhancin on *lepidopteran* PM proteins.

Previous studies have demonstrated that a *Trichoplusia ni* granulosis virus (TnGV) encodes an enhancin protein, a viral enhancing protein, that was identified as a metalloprotease. Enhancin degrades high molecular weight PM proteins *in vivo* and *in vitro*. In addition, the protein degradation initiated by these enhancins is correlated with the disruption of the structural integrity of the PM thereby "enhancing" viral infection. It was recently demonstrated that enhancin could degrade high molecular weight PM proteins from several lepidopterous species; however, the chemical nature and function of these proteins in baculovirus pathogenesis were previously unknown.

With a more complete knowledge of the proteinaceous components of the PM, and particularly the mucin-like proteins it will be possible to use that information to enhance the effectiveness of bio-engineered pesticides, recombinant viral vectors, enhance the defenses of transgenic plants, or protect insect vectors susceptible to attack by organisms utilizing enhancin or enhancin-like enzymes.

25

SUMMARY OF THE INVENTION

Briefly stated the current invention represents the disclosure of a novel intestinal insect mucin comprising two nearly identical isoforms, IIM14 and IIM22

respectively. The proteins are identical except for slightly different peptide length in some repetitive regions, which is common in mucin proteins. This IIM protein has been identified and cloned from *T. ni* larva. Its cDNA and amino acid sequences have been determined and are disclosed. The IIM protein has an approximate molecular mass of 400 kDa. These sequences are useful for the production of transgenic or recombinant vectors including viral, microorganism, cell, plant, or animals, wherein the virus, microorganism, cell, plant, or animal is the product of an insertion of a gene expression vector including a DNA that encodes an IIM protein sequence. Thereafter the engineered host of the IIM DNA sequence is capable of expressing said IIM protein in a functional form. One easily used host is the bacteria *Escherichia coli*.

Also useful is a purified and isolated recombinant DNA sequence comprising a DNA sequence that codes for an IIM protein. The recombinant DNA sequence used can be a cDNA sequence for either IIM14 or IIM22, SEQ. ID. 's No. 1; and 2 respectively. The current invention also provides for the use of the purified or recombinant proteins, IIM14 or IIM22, SEQ. ID. 's 3 or 4 respectively.

With the cloned IIM sequence it is possible to prepare an IIM protein or peptide by transforming a host cell with an expression vector comprising a promoter operatively linked to a nucleotide sequence which codes for a fusion protein wherein said fusion protein comprises a first protein or peptide fused directly or indirectly with a transfer molecule said first protein or peptide being a predetermined protein or peptide of a *T. ni* IIM protein. Then culturing the host cell under conditions such that the fusion protein is expressed in recoverable quantity. When harvesting the protein or peptide the cells must be collected, isolated, lysed, and the fusion protein purified from the cytosol.

A gene expression vector containing a recombinant DNA sequence encoding a *T. ni* IIM protein sequence can also be constructed with this technology. This is accomplished through the use of a recombinant plasmid adapted for insertion into and transformation of bacteria or transgenic plants such that these hosts can express either the IIM protein or antibodies to disrupt peritrophic membrane function and formation in larval pests. The antibodies expressed by the plant could bind to the mucin or its ligand

or portions the IIM protein could be expressed by the plant to result in competitive binding with the larvae's expressed mucin. As opposed to transformation with the entire IIM sequence, important peptide fragments or functional domains of the IIM protein can individually be transfected into expression vectors.

5

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows a schematic structure of the IIM protein.

FIG. 2 shows that greater amounts of FITC-dextran (3.2 nm dia) diffused across the peritrophic membrane of ligated *T.ni* alimentary canals taken from larvae fed on IgG containing diet for 2.5 hours.

10

FIG. 3 shows that the presence of IgG increased larval mortality due to AcMNPV infection.

FIG. 4 shows the chitin binding regions of the IIM protein shown in SEQ. ID. NO. 3 and SEQ. ID. NO. 4.

15

DESCRIPTION OF THE PREFERRED EMBODIMENT

The following detailed description describes the methods used to discover and sequence a novel invertebrate intestinal mucin (IIM), isolate cDNAs encoding this novel mucin, and determine the role of this mucin in the function of the peritrophic membrane during infection by a pathogenic viral organism.

20

Isolation and Analysis of A Novel Invertebrate Intestinal Mucin

PMs have long been proposed as selective physical barriers in invertebrate intestines. The primary components of PMs include chitin protein and glycoprotein, but

only one PM protein has been isolated and characterized thus far. PMs in invertebrates is analogous to vertebrate intestinal mucosal components that are secreted by epithelial cells. These vertebrate mucus secretions are composed primarily of one major constituent, intestinal mucin. Intestinal mucins from humans have been broadly studied, and the major human intestinal mucin (MUC2) was fully sequenced. Prior to the present invention, no intestinal mucin had been identified from invertebrates.

The present invention shows a novel invertebrate intestinal mucin (IIM). The novel mucin was first isolated from an insect larvae, *T. ni* larvae from a laboratory colony reared on a high wheat-germ diet. Midgut PM was dissected from mid-fifth instar *T. ni* larvae, thoroughly rinsed with de-ionized water, and stored at -70°C . PM proteins were solubilized by boiling PMs in SDS/PAGE sample buffer, and then separated by SDS/PAGE electrophoresis. The IIM protein disclosed herein is a new type of mucin that represents the first intestinal mucin identified from an invertebrate.

To prepare IIM for antiserum production, protein bands can be first visualized by staining the gel with 0.05% Coomassie blue R-250 in 40% methanol followed by de-staining with de-ionized water; this procedure can be followed by excision of the IIM band from the eletrophoresis gel. After equilibration in a SDS/PAGE running buffer, the IIM in the gel slice is electroeluted, and the preparation is purified and concentrated and re-suspended in PBS by ultrafiltration using a centrprep-30 concentrator (Amicon).

For general biochemical analyses, PM protein bands on the SDS/PAGE gel can be initially visualized by copper staining, which facilitates the excision of the IIM band. IIM from this gel slice is also electroeluted after copper ions are removed by washing the gel slice several times in 0.2 M EDTA. Subsequently, the eluted protein preparation is desalted by ultrafiltration.

To isolate and purify the IIM protein for amino acid composition analysis, the sodium phosphate-buffered SDS/PAGE system is used. The gel is stained with copper chloride after equilibration of the gel in 0.375 M Tris-HCl (pH 8.8) with 0.1% SDS. The IIM band is excised and the IIM is recovered by electroelution as described above;

the preparation is further desalted by extensive dialysis against de-ionized water and then lyophilized.

IIM from *T. ni* PMs is a 400-kDa protein on 3.5% SDS/PAGE gels. The association of the IIM with PMs is stable over a wide range of pH, in the presence of non-ionic and ionic detergents, and in the presence of protein denaturing reagents. Therefore, very little, or no IIM was present in the supernatants from these treatments. IIM, the predominant PM protein, could be released from the PM by a combination of 2% SDS plus 5 mM DTT, confirming that it was strongly associated with the chitin-containing PM matrix. The IIM was not extracted from the PM by boiling in 2% SDS for 10 min unless a reducing agent was included, demonstrating the presence of intermolecular disulfide bonding in native IIM

Amino acid composition analysis of IIM, indicated that IIM was rich in threonine (18.7%) proline (16.9%), and alanine (15.9%). These three amino acids accounted for 51.5% of the total amino acid residues in the protein, while aromatic amino acids accounted for less than 5% of the amino acid residues in the protein, and may account for the ability of IIM to be strongly associated to the invertebrate PM chitin fibrils. The IIM amino acid composition profile resembles that of a typical vertebrate mucin that is commonly rich in threonine, serine, proline, alanine, and glycine, and rare in aromatic amino acids.

Quantification of the protein and carbohydrate content of IIM indicated that it was highly glycosylated. Carbohydrate content on IIM accounted for 56% of the total IIM mass, with protein accounting for 44%. Terminal mannose residues and galactose β (1-3) N-acetylgalactosamine were detected on IIM by the specific binding of peanut agglutinin and *Galanthus nivalis* agglutinin (GNA). The lectin binding assays using IIM samples pretreated with either *O*-glycosidase or N-glycosidase showed no binding or significantly reduced binding of the lectins, confirming the positive recognition of *G. nivalis* agglutinin and peanut agglutinin to IIM. These results demonstrated that IIM has both N-glycosylation and *O*-glycosylation, since terminal mannose is present in N-linked carbohydrate moieties and galactose β (1-3) N-acetylgalactosamine is one type of *O*-linked carbohydrate moiety found in glycoproteins. In addition, removal of the

disaccharide, galactose β (1-3) N-acetylgalactosamine by *O*-glycosidase treatment, resulted in significant reduction (approx. 100 kDa) in the molecular weight of the IIM, further confirming the heavy *O*-glycosylation on IIM.

The experiments conducted demonstrated the highly protease-resistant nature of the isolated IIM. The stability of the IIM when exposed to digestive enzymes for long periods is aided by the *O*-linked carbohydrate moieties found in associated glycoproteins. The IIM was highly resistant to endogenous digestive even after a sixteen hour incubation, no degradation of IIM in PMs was observed. However, in the presence of *O*-glycosidase, IIM was quickly degraded. Control treatments using PMs with inactivated or inhibited endogenous midgut proteases, confirmed that the degradation of IIM in the presence of *O*-glycosidase was a result of hydrolysis by endogenous digestive proteases, following removal of the protective carbohydrate moiety, galactose β (1-3) N-acetylgalactosamine.

The isolated and sequenced IIM from *T. ni* PM resembles mammalian secretory mucins in several characteristics, including high *O*-glycosylation, possible intermolecular cross-linking disulfide bonds, high concentrations of threonine alanine and proline, and resistance to proteases. Selective removal of galactose β (1-3) N-acetylgalactosamine resulted in greatly increased susceptibility to proteolysis indicating that this *O*-Linked disaccharide plays an important role in protecting the IIM protein from digestive degradation. Unlike vertebrate mucins, insect PM proteins are embedded in a chitin fibril network. The inability to extract the IIM from PMs with various detergents and extreme conditions in the absence of a reducing agent demonstrate that IIM is tightly associated with the chitin-rich PM matrix and that disulfide bonding is seemingly important for this association.

Isolation and Sequencing of A Novel Invertebrate Intestinal Mucin cDNA

The present invention teaches cloned and sequenced full-length cDNAs for IIM from *T. ni*. IIM has a similar structural organization to human intestinal mucin, MUC2,

and is expressed in midgut tissue. Sequence analysis indicates potential chitin binding domains that may interact with the chitin present within the PM.

- A cDNA expression library was constructed from *T. ni* midgut mRNA. Midgut epithelial tissues were dissected from early to mid-fifth instar *T. ni* larvae in cold Rinaldini's solution. PMs with food contents and other attached tissues (i.e. fat bodies, trachea, and malpighian tubules) were quickly removed from the midgut epithelium. Isolated midgut epithelia were rinsed with cold Rinaldini's solution, quickly frozen in liquid nitrogen, and stored at -70°C prior to use. Midgut mRNA was isolated using the RNeasy total RNA isolation kit and the Oligotex mRNA isolation kit (Qiagen Inc., Chatsworth, CA), according to the manufacturer's specifications. The quality of mRNA was confirmed by Northern blot analysis, which showed no detectable degradation of mRNA after probing with β -tubulin DNA. The cDNA library was constructed from *T. ni* midgut mRNA using the ZAP-cDNA Gigapack Cloning Kit (Stratagene, La Jolla, CA), following the manufacturer's instructions. cDNA was unidirectionally ligated into the Uni-ZAP XR vector (Stratagene, La Jolla, CA) between the EcoRI and XhoI sites and packaged with the Gigapack II Gold package extract. The resultant cDNA library was amplified once at 50,000 plaques/15-cm plate in XL1-Blue MRF *E. coli* host cells.

- The library has a complexity of 2.35×10^6 plaques, of which over 99.5% were recombinants. Screening of the cDNA expression library for IIM cDNA clones was conducted using an IIM-specific polyclonal antiserum in conjunction with the pico Blue Immunoscreening Kit (Stratagene, La Jolla, CA), according to the manufacturer's specifications. The first round of screening was performed at a high density (i.e. 50,000 plaques/15-cm plate). Positive plaques were selected and further purified by screening at a low plating density (i.e. 20-50 plaques/10-cm plate). From purified positive phages the pBluescript SK (-) phagemid (Stratagene, La Jolla, CA) was excised *in vivo* following the ZAP-cDNA Gigapack cloning kit protocol.

- Screening of the library with the antiserum specific to IIM indicated that the mRNA for the IIM was abundant; 50 positive plaques were obtained from 50,000 plaques. Since only one in three plaques will be in the correct reading frame for protein expression, the frequency of IIM cDNA clones could be 1 in 333. From these 50

plaques, 20 positive plaques were further purified. From these 20 plaques, the pBluescript SK(-) phagemids were rescued by *in vivo* excision. Following restriction enzyme analysis to map the selected clones, two different full-length clones, pIIM14 and pIIM22, were chosen for sequencing.

5 Nested deletions from both orientations of the cDNA inserts were constructed using the Erase-a-Base System (Promega Corp., Madison, WI). Both strands of the cDNA were sequenced by automated cycle sequencing using T3 and T7 primers, complementary to the pBluescript SK(-) sequences flanking the cDNA inserts. DNA sequence analysis and a data base search were conducted using the DNASTAR
10 software package (DNASTAR Inc., Madison, WI) and BLAST data base search programs. Protein O-glycosylation sites were predicted following an O-GLYCBASE search.

 The cDNAs from both pIIM14 and pIIM22 were full-length clones, encoding a protein of 788 and 807 amino acid residues, respectively. The nucleotide sequence of
15 each is shown in SEQ. ID. NO. 1 & 2, respectively. The open reading frame in the cDNA from IIM14, was 57 base pairs shorter than in IIM22; otherwise, the open reading frames in these two clones were identical. IIM22 contains a putative polyadenylation signal consensus, AATAAA, located 331 base pairs downstream of the translation stop codon, TAA and 17 base pairs upstream of the poly(A). IIM14
20 contains a putative polyadenylation signal, AATTAA, located 15 base pairs upstream of the poly(A).

 The deduced protein sequences from IIM14 and IIM22 showed a hydrophilicity profile characteristic of a signal sequence at the N terminus of protein sequences. The N-terminal amino acid sequence determined from purified IIM indicated that the cDNA
25 clones encode a protein containing a signal peptide 25 amino acids long and confirmed that the cDNA clones code for the IIM. The amino acid composition of the deduced proteins from IIM14 and IIM22 were very similar to the composition of IIM isolated from *T. ni* further confirming that the cDNA clones code for the IIM. Protein sequence data reveal that there are four potential N-glycosylation sites. This is in agreement with
30 the biochemical analysis results which demonstrated that IIM has N-linked

glycosylation. The amino acid sequence of IIM14 and IIM22 is shown in SEQ. ID. NO. 3 & 4 respectively.

Referring to FIG. 1, the overall IIM sequences can be divided into six distinct regions based upon their sequence features. Figure 1 shows a schematic structure of the IIM protein. The amino acid composition of each region shows characteristics of a secreted epithelial mucin. Both the N-terminal and C-terminal domains, are rich in cysteine, which accounts for 8.2 and 7.8% of the total amino acid residues, respectively. Region III is rich in threonine, proline, and alanine (49.2, 16.2, and 21.5%, respectively) and contains two types of tandem repeats, TTTQAPT and AATTP, which are typical features for a mucin (6, 32). Region IV is similar to regions II and VI and contains 9.0% cysteine residues. Region V is another threonine-, Proline, and alanine-rich section, containing a repetitive sequence, TAAP. This region differed between IIM14 and IIM22 in sequence length, but the sequence features of the IIM protein isomers, and their respective cDNA clones were similar. The threonine-rich region (V), contains 25 TAAP repeats in IIM22.

Northern blot analysis of *T. ni* midgut RNA with a probe made from IIM22 showed a single band with a molecular size of 3.1 kilobase pairs, indicating that there was no similar polydispersity in IIM transcription, as is found in mammalian mucin transcripts.

Biochemical analysis has shown that IIM from *T. ni* midgut peritrophic membranes is a novel invertebrate intestinal mucin. The cDNA sequence presented here confirms the identity of this secreted invertebrate intestinal mucin. The overall structural organization of IIM is similar to human intestinal mucin, MUC2, which can be described as follows: (a) as a secreted mucin, the IIM contains a 25-amino acid signal peptide at the N terminus (region I); (b) relative to MUC2, which has two different tandem repeat domains interspersed by a cysteine-rich region that distinguishes MUC2 from other mucins, IIM also contains two threonine-rich tandem repeat regions (regions III and V) where potential O-glycosylation sites are located; and (c) the two tandem repeat regions are flanked by cysteine-rich regions (regions II, IV, and VI) (Fig. 1).

In comparison with MUC2, which contains more than 5100 amino acid residues, the apoprotein in IIM is relatively small. The mature IIM contains either 763 or 782 amino acid residues. Prediction of O-glycosylation using the O-GLYCBASE search program indicated that 127 of the 147 threonine residues and 5 of the 23 serine residues in IIM22 (excluding the signal peptide) were potential O-glycosylation sites. In regions III and V, all threonine residues, except the two at the boundaries of region III (at position 99) and region V (at position 486), were potential O-glycosylation sites. There is only one threonine in the non-tandem repeat domains (at position 314) marginally predicted as a potential O-glycosylation site. A PROSITE data base search using DNASTAR demonstrated four tentative N-glycosylation sites. All four sites were located within region V.

Regions III and V contain high levels of threonine, alanine, and proline, and do not contain any aromatic or sulfur-containing amino acids, which is similar to the corresponding domains in MUC2. IIM contains multiple repeating units. These repeating units are short compared with those found in mammalian mucins. Region III contains two tandem repeating sequences, TTTQAPT and AATTP, throughout the whole region. Region V contains an even shorter repeating unit, TAAP. The repeating units in this region are dispersed at four potential N-glycosylation sites and several other locations. Sequences TTVT(V/S)PP and TTAVPEI occur frequently in the disrupted locations in region V. The repeating sequences in IIM did not exhibit similarity to any known repeating sequences from other mucins.

The difference between cDNAs IIM14 and IIM22 is in region V. In this region, IIM14 contains 19 fewer amino acids than IIM22, which could be due to genetic polymorphism, as reported for human and other vertebrate mucin genes. Both IIM cDNAs contain G + C-rich repeated sequence units in region III and V. These G + C-rich repeated sequences (with χ -like sequence features), could be responsible for the evolution of genetic polymorphisms. This difference between IIM14 and IIM22 could also be the result of alternative splicing during RNA processing. Such a phenomenon has been observed in mucin gene expression. The AG at position 2005 and 2006 in

IIM22 could potentially serve as a 3'-splicing site, which would lead to a mRNA corresponding to IIM14.

The protein sequence features of the IIM are in agreement with the data from the biochemical analysis of IIM. The presence of N-glycosylation motifs and mucin-
 5 characteristic threonine-rich tandem repeats in the IIM sequence confirmed the presence of N-glycosylation and extensive O-glycosylation of IIM, previously analyzed by carbohydrate-specific lectin binding and specific glycosidase analyses.

Cysteine-rich domains are common in mucins and have been demonstrated to cause oligomerization of mucins by disulfide bonding. These cysteine-rich regions
 10 might also contain globular structures with intramolecular disulfide bonds. These protein regions could become exposed once the disulfide bonds are reduced. Disulfide bonds in the non-heavily O-glycosylated regions of IIM are involved in maintaining a digestive protease-resistant structure. However, protein sequence analysis did not show significant sequence similarity between the cysteine-rich regions in IIM and the
 15 cysteine-rich regions from MUC2, or other mammalian mucins. This is not surprising, since insects are phylogenetically very distant from mammals and since IIM is a constituent of a unique invertebrate chitin-containing structure.

IIM is tightly associated with the PM, and is a major structural constituent of the PM. These results indicate that IIM may have a high affinity to the chitinous fibril
 20 network of PMs. By computer-assisted sequence analysis, a protein fragment in region IV was aligned to two chitin binding domains in chitinases from a yeast, *Saccharomyces cerevisiae*, and a fungus, *Rhizopus oligosporus*. In addition to region IV, sequences in regions II and VI also show a certain degree of similarity to the chitin binding domains described above; however, the levels of similarity were lower than
 25 that found in region IV. In a recent report, a non-mucin insect PM protein from *Lucilia cuprina*, peritrophin-44, showed binding capability to chitin, but it did not show significant sequence similarity to known chitin binding sequences. However, the cysteine-rich domains with peritrophin-44 shared the same structural feature, a six-cysteine-containing sequence present in cysteine-rich domains in chitinases.

Surprisingly, the sequence features of IIM in the cysteine-rich regions are similar to what Elvin et al. proposed for peritrophin-44. Almost all sequences in regions II, IV, and VI are composed of such a six-cysteine consensus. This result supports the conclusion that IIM may tightly bind to the chitin network of PM in the non-glycosylated cysteine-rich regions. The strong binding of IIM to chitin could be a very important factor for the formation of PMs in invertebrates and aid in the stability of the chitin network. Based on the structural characteristics of IIM and the strong binding associated with IIM and chitin, it is likely that the chitin fibrils in PMs are protected from enzymatic degradation by IIM. Considering the biochemical properties of IIM and the putative chitin binding sequences in non-glycosylated regions in IIM, the IIM protein backbone is protected from degradation in the hydrolytic enzyme-rich midgut environment by two different mechanisms: (a) the densely O-glycosylated regions (regions III and V) are protected by oligosaccharide moieties; and (b) the cysteine-rich non-glycosylated or less glycosylated regions (regions II, IV, and VI) are protected by disulfide covalent bonding forming a "buried" structure or by the protein binding to chitin in the PM. The mucin nature and chitin binding capability of IIM can explain the high resistance of IIM to midgut digestive enzymes and the protective functions of PMs in invertebrates, especially in insects. Any reagents with the potential effect of damaging IIM, such as baculovirus enhancins or reducing agents, will result in the destruction or attenuation of the protective role of the PM against parasites and other microorganisms.

Localization of Expression of the Mucin in the Peritrophic Membrane

By immunolocalization in tissue sections, it was determined that IIM is expressed in midgut tissues.

The IIM from *T. ni* larvae was localized by immunocytochemistry with the antiserum to IIM. An antiserum to IIM was generated by immunizing a Flemish Giant/Chinchilla Cross rabbit with purified IIM from *T. ni* PMs. Preimmune serum from the rabbit was collected and used as a control for immuno-detection of IIM. Fourth instar *T. ni* larvae were fixed in 4% paraformaldehyde overnight at 4°C and

embedded in paraffin. After tissue sectioning and de-waxing immunostaining was performed as follows: sections on glass slides were blocked for nonspecific staining with 3% bovine serum albumin in phosphate-buffered saline, followed by incubation with antiserum against IIM in phosphate-buffered saline containing 3% bovine serum albumin. After incubation with the first antiserum, the sections were washed with phosphate-buffered saline and incubated with a secondary antibody against rabbit IgG conjugated with colloidal gold (Sigma). Following secondary antibody incubation and subsequent washing, the sections were fixed with 2.5% glutaraldehyde. Immunogold staining was intensified by silver enhancement using the Silver Enhancer kit (Sigma). The immunostained sections were counterstained with hematoxylin and eosin and examined by microscopy.

Microscopic observations showed that IIM was localized in the peritrophic membrane and in the area surrounding the midgut epithelial brush border. Observation at a high magnification demonstrated that IIM could be secreted from goblet cells of the midgut epithelium. Immunostaining with preimmune serum from the same rabbit used to generate the anti-IIM antiserum did not show any positive reaction. In addition to the midgut, positive staining was occasionally observed in malpighian tubules on the lumen side. To verify whether this occasional positive staining in malpighian tubules was specific to IIM and to test whether IIM was present in other tissues, a Western blot analysis of extracts from various tissues of *T. ni* larvae using anti-IIM antiserum was conducted.

Tissues were isolated from fifth instar *T. ni* larvae and rinsed with phosphate-buffered saline. The tissues were then homogenized and boiled in 0.0625 M Tris-HCl (pH 6.8) containing 2% SDS, 5% Beta-mercaptoethanol, and 10% glycerol. Undissolved materials were removed by centrifugation. Protein concentrations in the supernatants were estimated using the Bradford protein assay. One microgram of protein from each tissue extract, except for the PM extract, for which 0.04 μ g of protein was used, was loaded onto the gel. Proteins were separated by SDS-PAGE, followed by blotting onto Immobilon membrane (Millipore Corp., Bedford, MA), and probed with anti-IIM antiserum.

The Western blot analysis showed that IIM was primarily present in the non-cellular PM. A broad band at 200 kDa could also be detected in the PM extract when this sample was overloaded. This band is considered a degradation product of IIM by active midgut digestive enzymes, since the PM moved through the digestive tract. The midgut was the only tissue in which a significant amount of IIM was detected. Besides the IIM band, some lower molecular weight bands were also present in the midgut extract. These bands possibly were the IIM protein in the process of glycosylation but not yet fully glycosylated. The extract from malpighian tubules did not show any positive staining at the gel position for IIM. Some weak positive staining was detected in the extract from hemolymph with a major broad band between 66 and 97 kDa. Salivary gland, fat body, and epidermis extracts did not show any positive reaction to the anti-IIM antiserum. The bands detected in the malpighian tubules and hemolymph did not show the correct molecular weight corresponding to IM, and the reactivity to the anti-IIM serum was very low. Therefore, the proteins represented by these bands do not indicate the presence of IIM in tissues other than the PM.

Localization of IIM by immuno cytochemistry indicates that IIM is primarily expressed in the midgut tissue and is likely to be secreted by goblet cells. Interestingly, this is similar to the secretion of mucins by goblet cells in vertebrate intestinal epithelium.

Peritrophic Membrane Secretion Patterns of Invertebrate Intestinal Mucin

T. ni PM first appears in larvae before feeding starts and is present along the entire length of the mesenteron. IIM plays a significant role in the formation and function of the peritrophic membrane. To ascertain the secretion patterns of IIM, PM structure and secretion patterns were examined in the anterior, middle and posterior regions of the mesenteron.

Third instar larvae were allowed to fed on diet up to 24 hours. Prior to dissection, larvae were placed in wax-filled Petri dishes, stretched and pinned through the head capsule and telson, using pins held with forceps. The larvae were then flooded

with cold fixative (3.2% formaldehyde, 5% glutaraldehyde in 0.1 M Sorensen's phosphate buffer, pH 7.2 containing 3% sucrose) and dissected to remove the cuticle. The exposed alimentary canal was fixed for 2 hours at 4°C, washed in 0.1 M Sorensen's phosphate buffer containing 3% sucrose for 2 hours, post-fixed in 1% osmium tetroxide
 5 in 0.1 M sodium cacodylate buffer, washed in double distilled water (ddw), *stained en bloc* for 4 hours with 2% aqueous uranyl acetate (on ice), washed in cold ddw for 0.5 hour, and then dehydrated in an ascending ethanol series from 50 to 100%. The specimens then were infiltrated with a 1:2 mixture of ethanol: Spurr's resin for 1 hour, followed by a 1:1 mixture for 2 hours, and lastly placed in 100% Spurr's resin
 10 overnight. The specimens in resin were embedded in molds and cured for 60°C for 24 hours

Other specimens also were embedded in LR White resin for immunocytochemical procedures. Dissections were performed as above except the fixative contained 4% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M phosphate
 15 buffer saline (PBS), pH 7.2. Freshly dissected alimentary canals were fixed in this solution overnight, incubated in 0.1 M ammonium chloride in PBS for 1 hour, washed in PBS for 2 hours, and dehydrated in ascending ethanol series from 50 to 100%. The specimens were resin infiltrated with a 1:1 LR White: ethanol mixture for 2 hours, transferred to 100% resin with one change, and kept overnight to allow complete resin
 20 infiltration. The specimens in resin were loaded into gelatin capsules and allowed to polymerize at 50°C overnight. Thick sections (0.5µm) were cut using glass knives on Reichert Ultramicrotome. For transmission electron microscopy (TEM), thin sections were cut using a diamond knife and mounted on naked or formvar-coated nickel grids and observed on a Phillips EM 201 transmission electron microscope.

25 For wheat germ agglutinin (WGA) staining, thin sections were incubated for 1 hours at room temperature in blocking buffer [0.01 M PBS (pH 7.2) containing 1% cold water fish gelatin, 0.075% Tween 20, and 0.075% Triton X-100] and subsequently incubated in a 1:100 dilution of 20 nm gold-labeled WGA (20 µg/ml) (E-Y
 Laboratories, San Mateo, CA) in blocking buffer for 1 hour. After incubation, grids
 30 were washed with PBS, ddw and stained with uranyl acetate (UA) and lead citrate

(PbC). Cytochemical controls consisted of addition of 1 part 10 mM chitotriose with 1 part WGA solution at twice the above concentration.

Invertebrate intestinal mucin (IIM) was localized in thin sections which were first blocked in blocking buffer then incubated in a 1:300 dilution of anti-IIM preparation for 1 hour. Sections were then washed in multiple changes of blocking buffer for 1 hour then incubated in 1:100 dilution of 20 nm gold conjugated goat anti-rabbit IgG (E-Y Laboratories, San Mateo, CA) for 1 hour. Sections were then washed with blocking buffer, PBS, ddw and stained with UA and PbC. Cytochemical controls were first incubated in a 1:300 dilution of rabbit preimmune serum for 1 h, washed in PBS for 1 hours and incubated in secondary antibody as described above. Scanning electron microscopy (SEM) was performed on *T. ni* larvae. The midgut and PM were dissected and placed in Karnovsky's fixative for 2 hours. The specimens were then dehydrated in an ascending ethanol series from 70 to 100%, critical point dried, fixed to aluminum stubs with silver paste, sputter coated with gold-palladium, and viewed in an AMR-100A scanning electron microscope.

PM was present along the entire length of the mesenteron. In the most anterior midgut region examined, PM appeared as a single thin structure located between the stomodeal valves and midgut epithelium. Slightly posterior to this region (about 2 mm) PM appeared slightly thicker. This slight increase in thickness may be the result of the association of fine thread-like material to the delaminated PM. In the middle region of the mesenteron, the morphology of the PM changed to a more robust structure composed of compact layers. Similar in appearance to PMs located in the middle portion of the mesenteron, PM in the posterior mesenteron (just adjacent to the proctodeum) can be seen at lower magnifications partitioning dietary plant cell walls and microbes from the underlying midgut epithelium.

Observations taken from electron micrographs shows PM formation begins with the appearance of fine fibrous-like material within the brush border of the anterior mesenteron. These nascent PMs first appear in the upper third of the microvillar brush border as diffuse structures. Probing these regions with anti-IIM and WGA-gold, produce discrete lines of labeling confined to these fibrous-like structures. These

staining patterns indicate IIM and chitin (or N-acetyl-D-glucosamine containing structures) to be present in the nascent PM. This same binding pattern can be seen at the tips of the microvillar brush border demonstrating that nascent PM moves apically for delamination into midgut lumen. These delaminated PMs have a fibrous appearance and bind both WGA-gold and anti-IIM. Scanning electron microscopy (SEM) of the anterior midgut region revealed a microvillar brush border inundated with various amounts of material. Interestingly, SEM apparently captured individual secretion events where PM was resting above cells. At higher magnifications, these newly delaminated PMs possessed fibrous-like material, which is mostly obscured by smooth matrix material. Finally, these individual secretion events coalesce form a large smooth and continuous PM which now conceals the underlying midgut epithelium.

To determine when PM first appears within the midgut lumen, third instar and newly molted third instar larvae were examined for the presence of PM. Although PM was not found in the pharate stage, there was localization of anti-IIM within the brush border (data not shown). Examination of newly ecdysed larvae (which have just passed their exuviae across the telson) showed a well-developed PM within the middle part of the midgut. In these larvae, the anterior midgut showed the presence of diffuse material packed between the interstices of microvilli. This material labeled extensively with anti-IIM and was present in the gut lumen above newly secreted PM. Interestingly, there was an association of this diffuse material to delaminated PMs. Finally, the staining patterns of IIM were investigated through out the length of the mesenteron. Cells located in the anterior midgut possessed vesicles, which were extensively labeled with anti-IIM. In the posterior regions, anti-IIM localized to microvillar brush border to columnar epithelial cells adjacent to goblet cells. This same phenomenon was observed in the brush border of cells from the middle portion of the mesenteron.

At the entrance of the mesenteron, the PM was observed as a thin structure sandwiched between the tips of the microvillar brush border and intima of the stomodeal valves. This delicate-looking membrane increased in thickness as it moved in a posterior direction toward the proctodaeum. The delamination of PM from the microvillar brush border was only observed in the anterior mesenteron. No PM

delamination events were seen in the middle or posterior mesenteron. Furthermore, sections representing the mid- and posterior mesenteron showed no discrete lines of labeling within the brush border when probed with anti-IIM or WGA-gold. This observation demonstrates that chitin and IIM do not aggregate to form nascent PM in regions past the anterior mesenteron. Within the anterior mesenteron, PM formation begins with the secretion of chitin and matrix material (IIM). These PM components appear to first aggregate within the upper part of the brush border to form a nascent PM. This is followed by delamination of PM into the midgut lumen. Even though PM delamination events appears to be restricted to the anterior mesenteron, there is secretion of IIM from cells located in the middle and posterior midgut. In the middle and posterior mesenteron, the majority of anti-IIM localized to the brush border. Secretion of IIM through out the entire length of the mesenteron may account for the observed increase in PM thickness. Interestingly, IIM secretion was often localized to columnar epithelial cells directly adjacent to goblet cells.

Our observations that PM formation is restricted to the anterior part of the midgut is consistent with previous studies. In one study, the European corn borer (ECB, *Ostrinia nubilalis*) larval PM formation was found to be limited to the anterior mesenteron. In this region, ECB nascent PM was embedded within the brush border and stained with WGA-gold (indicating the presence of chitin containing structures). Even though the authors were able to determine an anterior site of chitin substructure assembly and delamination, they were unable to directly determine where protein matrix was synthesized and secreted. The current disclosure demonstrates that the midgut region is responsible for the secretion of protein matrix in *T. ni* larvae. By probing the midgut for the major protein moiety IIM, it was determined that the chitin substructure and protein matrix (IIM) apparently are secreted together from cells located within the anterior part of the mesenteron. These results are consistent with the SEM observations which show fibrous linear structures (assumed to be chitin microfibrils) embedded in a proteinaceous matrix. Finally, another very interesting observation is the secretion of IIM through out the mesenteron. This whole midgut secretion phenomenon may provide additional amounts of matrix material to damaged

PMs. This may in turn preclude microbes and rough dietary components access to the midgut epithelium.

The Role of the Mucin in the Function of the Peritrophic Membrane and

Baculovirus Infection

A baculovirus enhancin, which is encoded and carried by specific baculoviruses, has mucin-degrading activity both *in vitro* and *in vivo*. The *in vivo* degradation of IIM by enhancin was correlated with the enhancement of baculovirus infections in insects. These findings show that viruses have evolved a novel strategy to overcome intestinal mucinous barriers against microorganisms by utilizing a mucin-degrading enzyme.

Incubation of IIM with *Tn* enhancin showed that the enhancin had activity against IIM. To demonstrate proteolytic activity by TnGV enhancin against IIM, purified IIM was incubated with 1.25 µg/ml TnGV enhancin in 0.05 M Tris-HCl buffer (pH 7.5) containing a cocktail of protease inhibitors minus the metalloprotease inhibitor, EDTA at 37°C for 3 hours or overnight. The degradation of IIM was examined by SDS/PAGE analysis. A parallel treatment of IIM without enhancin was included as a control. The degradation products of IIM displayed a banding pattern similar to that observed during incubation of intact PMs with enhancin. To confirm the metalloprotease nature of enhancin, IIM was incubated with TnGV enhancin in the presence of 10 mM EDTA. The addition of 10 mM EDTA to the incubation buffer blocked the digestion of the IIM and confirmed the metalloprotease nature of enhancin.

In vivo IIM degradation assays with *T. ni* neonate larvae demonstrated that enhancin degraded IIM in the midgut of living insects and that the degree of degradation appeared to be dose-dependent. Two *in vivo* assays were developed to include neonate and fifth instar *T. ni* larvae, based on the methods employed to determine the efficacy of an enhancin on virus infections. The *in vivo* neonate IIM assay and a concomitant virus bioassay were conducted by feeding *T. ni* neonate larvae

with inoculum droplets containing 10^5 occlusion bodies/ml of AcMNPV, and varying doses of TnGV enhancin, as described by Wang et al. Following ingestion of the inoculum, 25 larvae from each treatment were transferred onto artificial diet, incubated at 28°C for 90 minutes, and collected for Western blot analysis using an antiserum specific to IIM. For Western blot analysis, the larvae were homogenized in 100 μ l of SDS/PAGE sample buffer. Subsequently, 4 μ l of each sample was electrophoresed through a 7.5% SDS/PAGE gel, blotted, and then probed with anti-IIM antiserum.

To assess the correlation between the extent of IIM degradation in living insects and the degree of enhanced AcMNPV infection by TnGV enhancin, 60 neonate larvae from each feeding group were also collected and individually reared on artificial diet. Viral infections were monitored and examined throughout the whole insect larval developmental stages, as described by Wang et al. The extent of degradation of IIM was correlated with increased AcMNPV infection in larvae. This enhanced mortality was statistically significant and can be presented by the regression analysis: Probit mortality = $4.72 + 0.256 \times \text{enhancin dose (ng/larva)}$ ($R^2 = 99.2$; $P = 0.004$).

The *in vivo* IIM degradation assay was also conducted by feeding fifth instar *T. ni* larvae with TnGV enhancin and analyzing the residual IIM in the fecal pellets. Early fifth instar *T. ni* larvae were fed 10 μ l of inoculum containing 5% sucrose, 10 μ g/ml blue food coloring, and 5 μ g TnGV enhancin in 25 mM sodium carbonate buffer (pH 10.5). Afterward, the larvae were transferred to individual rearing cups containing artificial diet and incubated at 28°C. During the incubation period, enhancin will digest the IIM present in the PM. PMs are secreted within the intestine and later excreted with fecal pellets, which are normally ensheathed within the remnants of a PM. The first three fecal pellets marked with blue food coloring therefore were collected and subjected to Western blot analysis using the IIM-specific antiserum. The *in vivo* IIM-degradation assay using fifth instar larvae showed that IIM was present in the control fecal pellets and exhibited some minor degradation. However, no IIM was detected in the fecal pellets collected from the TnGV enhancin-fed larvae, confirming that enhancin completely degraded IIM in the digestive tract of living insects.

The presence of an IIM protein and its degradation by enhancin is not restricted to the species, *T. ni*. Another mucin, similar to the IIM from *T. ni* PMs, was also isolated from *Pseudaletia unipuncta* PMs and biochemically characterized. This mucin is also degraded by the TnGV enhancin and degradation was correlated with enhanced baculovirus infections in *P. unipuncta* larvae.

The PDV that crossed enhancin treated *T. ni* PMs was infectious, as was demonstrated by increased mortality rates compared to control treatments (Table 1). The effect of enhancin on PM permeability to infectious viruses was confirmed using a second insect species, *P. unipuncta*. Enhancin had a significant effect on PM permeability, although the *P. unipuncta* PMs appeared to be more permeable to the virus (Table 1).

In lepidopterous larvae, the PM is a structure containing pores which may vary in size among different insect species. Low level permeability of untreated *T. ni* PMs to blue dextran 2000 appears to confirm the presence of naturally occurring pores within the PM matrix. Although the purpose of this study was not to determine the approximate pore size of *T. ni* or *P. unipuncta* PMs, these studies did show that control *T. ni* PMs were permeable to blue dextran (diameter: 54nm) but were almost impermeable to AcMNPV PDV (186nm diameter x 357nm length) over an 8-hour period. Insect bioassays also suggested that untreated *P. unipuncta* PMs probably had a larger pore size and allowed passage of more PDV particles than PMs from *T. ni* since control mortality values were higher for samples obtained from *P. unipuncta* PM permeability experiments (1% vs. 38%, respectively; Table 1).

Table 1. *T. ni* neonate bioassays showing increased permeability of *T. ni* and *Pseudaletia unipuncta* peritrophic membrane to AcMNPV PDV following treatment with enhancin.

Treatment	<i>T. ni</i> Peritrophic Matrix ^a			<i>P. unipuncta</i> Peritrophic Matrix ^b		
	Total Insects Tested	Avg. % Mortality \pm SE	t-Test (p)	Total Insects Tested	Avg. % Mortality \pm SE	t-Test (p)

PM ^e enhancin treated	90	15.6 ± 2.9	150	90.7 ± 2.9
		< 0.01		< 0.01
PM control	90	1.0 ± 0.3	150	38.0 ± 8.2
AcMNPV PDV control	90	97.8 ± 2.2	150	100 ± 0
a. Summary of 3 independent tests. b. Summary of 5 independent tests. c. PMs mounted in a dual chamber permeability apparatus were treated with 3 mg/ml enhancin for 1 hour and samples were collected 16 hours post-treatment.				

5

Our work showed that sephacryl-purified enhancin preparations contain traces of contaminating insect proteases. In a subsequent study, Lepore et al. (1996) showed that extensive purification of enhancin by ion exchange chromatography and immobilized α -macroglobulin removed the contaminating proteases without

10 diminishing the *in vivo* and *in vitro* activity of enhancin, thus providing evidence that these proteases did not have a role in the enhancement of infections. Furthermore, in that same study, Lepore, et al. (1996) also demonstrated that purified TnGV enhancin, expressed by a recombinant AcMNPV in insect cells, was active on insect PMs.

Addition of protease inhibitors provided evidence that potential contaminating

15 proteases did not have a role in increasing the PM permeability. The metalloprotease inhibitor EDTA was able to inhibit the action of enhancin. Although there is no published evidence that granulosis viruses encode a chitinase, it was recently reported that such a functional gene was present in the nuclear polyhedrosis virus, AcMNPV. To rule out the effect of any possible chitinase contamination in our enhancin

20 preparation a potent chitinase inhibitor was used and no effect on the ability of enhancin to increase PM permeability was found. Chitinase activity was not detected in our preparations using a chitinase activity assay.

Previous studies with enhancin suggested that the PM, though clearly not an impenetrable barrier, does reduce the exposure of susceptible midgut cells to

baculoviruses. It appears that some insect viruses may have evolved similar mechanisms to degrade the structural integrity of the PM and facilitate the passage of infectious virus. Derksen and Granados (1988) reported that an unidentified factor in the polyhedrin fraction of AcMNPV was able to affect the protein profile and structure of the PM. This observation was recently confirmed by Faulkner et al. (1997) who found that OBs from both a mutant and wild-type AcMNPV could degrade the PM from *T. ni* larvae. Furthermore, the presence of an enhancin-type gene was recently reported from *Lymantria dispar* nuclear polyhedrosis virus suggesting that other similar nuclear polyhedrosis viruses (NPVs) may carry enhancin genes. Begon et al. (1993) reported *Plodia interpunctella* GV (PiGV) OBs caused dramatic and significant effects of the PM structure from the same species and concluded that the PM provided a barrier to PiGV infection at lower virus doses.

Although there have been many investigations concerning the mode of action of enhancin, prior to the work of inventors consensus has not been reached. It was previously reported that an enhancin from PuGV acted on the plasma membrane of midgut cells and cultured insect cells, facilitating the entry of virus particles into the cells by providing attachment sites or facilitating membrane fusion for the virus particles. Based upon the work described in this patent application, the inventors believe a major role of GV enhancins is to disrupt the structural integrity and increase the permeability of the PM to baculovirus particles. Our previous studies demonstrated that enhancin from TnGV digested a specific major PM protein, insect intestinal mucin. The digestion of this PM mucin and the resulting degradation of the PM structure was correlated with enhanced baculovirus infection of insect larvae. It is reasonable to conclude that the disruption of the PM structure resulted in the increased porosity of the PM, thereby facilitating the infection of the underlying epithelial cells. Thus, these viral-encoded proteins appear to play an important role in baculovirus pathogenesis.

T. ni PMs are present in all larval instars and at all stages between molts. Therefore, IIM may play a protective role throughout the entire larval period. No mucin degrading protease has been previously reported to be associated with a virus to assist the penetration of a pathogen through a mucinous protective barrier; therefore, this

study represents a novel concept in animal virus pathogenesis. The present invention enables further studies on the specific recognition sites and cleavage of mucins by baculovirus enhancins, and the biological properties of IIM and enhancins. Furthermore, use of IIM degrading enzymes in recombinant plants or baculoviruses will decrease larval growth and increase the pathogenesis of virus infections.

Having discovered the IIM protein and its function, the inventors were able to develop applications for use of the novel cDNA sequences and the recombinant protein.

Diet Incorporation Experiments Using Anti-IIM Serum

Polyclonal antibodies against an insect peritrophic membrane (PM) protein from the Australian blowfly, *Lucilia cuprina* inhibited growth and caused mortality of blowfly larvae. It was reported that this biological response was caused by the PM antibody, which blocked nutrient diffusion across the PM. The present invention includes the discovery that a polyclonal antibody against the *T. ni* PM mucin (IIM) has an adverse effect on *T. ni* growth and survival.

Mucin was prepared from *T. ni* fifth instar larval PM by preparative PAGE. The gel was stained by CuCl_2 (0.3M) for 5 min and the band containing mucin was isolated and destained in 0.2 M EDTA. Mucin was further eluted from the gel slices by electroelution, and used to immunized rabbit following a standard rabbit immunization protocol. 0.2 mg mucin was used per injection for a total of 3 injections. Serum was collected at 6 weeks after the first injection and IgG was purified from the serum using caprylic acid and ammonium sulfate methods (Harlow, E. & Lane, D. 1988-- Antibody, a laboratory manual. Cold Spring Harbor Laboratory). Control rabbit IgG was also purified from normal rabbit serum (Gibco).

A laboratory colony of *T. ni* reared on high wheat germ diet was used in these experiments. To prepare diet incorporated with IgG, high wheat germ diet was prepared but with less water (10% less than the final diet volume). After mixing all the components, the diet was allowed to cool gradually to 45°C, and IgG solution was

added with vigorous stirring. Heat inactivation experiments showed that the immunoreactivity of the anti-IIM serum was reduced above 60°C (data not shown). Water was added when necessary to adjust the volume. The diet prepared in this way has exactly the same concentration of each component as normal high wheat germ diet, with the exception of the addition of IgG. The final concentration of IgG in the diet was 20% of the original IgG concentration (V/V) in original anti-IIM serum. The diet was aliquoted (2.5 mls/cup) into 1 oz cups which was sufficient diet to allow the larvae to develop into pupae.

T. ni neonates were placed individually into the cups with standard (no IgG) or IgG-incorporated diet. This time point was designated as time zero. The larvae were incubated at 28°C and the larval growth was recorded every 8 hours. The larval weight was also recorded at the 3rd and 6th day. Pupal weight was measured when all the larvae had pupated. The experiment was conducted twice with 30 insects per treatment.

Incorporation of IgG into the diet had a significant effect on *T. ni* larval development (Table 2). Although control rabbit IgG containing diet had a strong effect on larval growth compared to larvae on standard wheat germ diet, the anti-IIM IgG treatment had an even stronger and statistically significant effect. The duration of growth from neonate to pupa was delayed in anti-IIM IgG fed larvae, and was significantly longer than control IgG containing diet fed larvae. Similarly, the anti-IIM IgG fed larvae had the lowest weight at day 3 and day 6, and their weight was also significantly lower than larvae fed on control IgG diet at day 6 in both experiment and at day 3 for experiment 2. No difference in pupal weight was found between all the treatments in both experiments.

Table 2. Comparison of *T. ni* larval and pupal weights and developmental duration from neonate to pupa.

Treatment	# of insect	Duration from Neonates to Pupae		Larval Weight at Day 3		Larval Weight at Day 6		Pupal Weight	
		(hr±SE)	p*	(mg±SE)	p*	(mg±SE)	p*	(mg±SE)	p*
Exp. 1- Control	30	201.47±1.71		6.45±0.49		142.50±7.35		225.57±3.43	
Exp. 1- Normal IgG	30	212.48±2.78	0.05	3.91±0.33	0.11	93.65±6.93	0.01	221.16±2.94	0.62

Exp. 1-Anti-IIM IgG	30	219.07±1.79		3.28±0.19		72.47±4.23		223.28±3.10	
Exp. 2-Control	30	193.6±1.46		5.78±0.30		167.17±6.26		223.83±3.21	
Exp. 2-Normal IgG	30	206.90±2.91		3.99±0.24		112.93±9.39		224.20±3.04	
Exp. 2-Anti-IIM IgG	30	216.53±2.82	0.02	3.17±0.24	0.02	88.94±6.82	0.03	227.70±3.29	0.45

* From t-test comparing weight or duration between larvae on normal IgG diet and anti-IIM IgG diet.

An effect of anti-IIM IgG on *T. ni* larval development was observed. Compared with larvae fed on control rabbit IgG containing diet, the larvae on anti-IIM IgG containing diet required a longer time to develop from a neonate to pupa, and had a lower larval weight at day 3 and day 6. In most cases, the differences were statistically significant. Since no difference in pupal weight for the various treatments was observed, the differences in larval weight might be caused by a difference in speed of development. It is clear that the presence of anti-IIM IgG in the diet resulted in significantly slower growth of *T. ni* larvae. Anti-IIM IgG binds to the major protein on the insect peritrophic membrane, which could result in the blockage of nutrient flow through the peritrophic membrane.

The control rabbit IgG had a significant effect on larval development, compared with larvae growing on standard high wheat germ diet. Several different commercial rabbit sera were compared (two batches from Sigma, and one from Gibco), and they all showed a similar effect on *T. ni* development. The reason for this is not clear. No major cross-reaction of normal rabbit IgG to *T. ni* peritrophic membrane components was detected in western blot experiments. It is possible that IgG somehow interferes with the digestive physiology of the insect, or has some feeding deterrent effect. A similar phenomena was also reported by Casu et al. (1997) where the growth of the blood feeding insect, *Lucilia cuprina* was inhibited in the presence of high concentration of normal control IgG.

The design of the experiments conducted were effected by the relatively low amount of serum that can be obtained from rabbits (i.e., 70 ml/rabbit) for use in experiments. Using a PM permeability chamber it was also demonstrated that anti-IIM

serum could block the permeability of the PM to particles smaller than 5 nm. This demonstrates that such a phenomenon, if it occurred *in vivo*, might have a detrimental effect on the nutritional physiology of the insect. These data demonstrates that the delivery of anti-IIM antibodies through transgenic plants is a novel approach for
 5 affecting insect development or mortality.

Altered *In Situ* Peritrophic Membrane Permeability

The present invention includes the discovery that feeding larvae anti-IIM IgG affects the permeability of the peritrophic membrane.

10 Fifth instar larvae reared on a high wheat germ diet were starved for 1 hours. Starved larvae were then injected *per os* with 20 μ l of anti-IIM IgG (2X concentrated) solution and placed on a high wheat germ diet containing an equivalent of 20% anti-IIM IgG and 4% (dry wt) FITC-Dextran (3.2 nm diam.). Controls larvae were injected
 15 *per os* with either PBS or normal serum IgG and placed on their respective diets. After feeding for 2.5 hours at 28°C, larvae were chilled on ice and dissected under saline buffer to expose the alimentary canal. Once the esophagus and proctodeum were ligated, a small hole (0.2 x 2 mm) was made to expose the PM. This hole was made in the middle portion of the midgut just immediately anterior to the anastomosing
 20 malpighian tubules. These mesenterons were then severed from the alimentary tract and placed in a small dish which contained 15-ml buffer. To help remove any free FITC-dextran, the ligated midgut was rinsed 3 times with 15-ml aliquots of buffer. When the final rinse solution was removed, the ligated midgut was re-suspended in 4 ml of saline buffer and incubated under gentle mixing. Aliquots of incubating solutions were
 25 fluorescent plate reader set at a 485-nm excitation of 530-nm emission.

The permeability characteristics of PMs to passage of FITC-dextran is presented below. *T. ni* larvae fed on diets containing IIM-IgG showed greater amounts of FITC-dextran in the incubating buffer as compared to those larvae fed on diets containing

normal serum and PBS (Fig. 2). Intact, ligated midgut showed FITC-dextran is confined within the midgut proper and that the midgut wall acts as a barrier to the 3.2 nm FITC-dextran.

Figure 2 shows permeability characteristics of ligated midgut from larvae fed diet containing either IIM-IgG, normal serum IgG, or PBS. An intact, ligated midgut showed low passage of FITC-dextran across midgut wall. There was more FITC-dextran present in the incubation buffer of IIM-IgG ligated midgut. Each treatment and control are replicated.

In contrast, insect larvae that have fed on diets containing IIM-IgG have a greater PM permeability to FITC-dextran. The final amount of fluorescence in the incubating medium (at 3 hours) was greatest from IIM-IgG fed insects. One possible explanation for this is that ingested IgG may bind to newly secreted IIM thus altering the amounts of protein matrix available for normal PM synthesis. These results are contradictory when compared to the blocking ability of anti-IIM to passage of FITC-dextran in the *in vitro* studies of peritrophic membrane permeability. In those *in vitro* studies, PMs were dissected and treated with serum. In the *in vivo* studies, insects are fed IIM-IgG for 2.5 hours. Therefore, IgG may bind to delaminated PM resulting in a "short term blockage" which could be followed by a subsequent "long term structural alteration" of PM. PM alterations could result from antibody competing for IIM (especially during PM formation). These interactions could produce very porous PMs. IIM-IgG induced PM structural abnormalities may be an appropriate explanation for the observed weight changes and increased development time of larvae from the diet incorporation experiments.

Thus, the use of IIM anti-serum against larval pests would first block the insects ability to absorb nutrients and then dramatically increase the infection rate of ingested baculoviruses due to the increased permeability. Furthermore, this disruption effect can be caused by antibodies expressed by a transgenic plant binding to IIM or expression of portions of the IIM by the plant that competitively bind to the peritrophic membrane.

Effect of IIM IgG on AcMNPV Infection

Based on the observations that IIM IgG may interfere with PM structure, a viurs bioassay was conducted to determine if the ingestion of IIM IgG along with AcMNPV would increase larval mortality due to viral infeciton. A neonate droplet bioassay was conducted as reported by Lepore *et al.* (1996) except IgG replaced enhancin. *T.ni* neonates consumed approximately 1 occlusion body and 10 nl of IgG solution profied from normal rabbit serum or anti-IIM serum. After droplet consumption, neonates were placed on high wheat germ diet and monitored for mortality due to AcMNPV infection. In two preliminary experiments there was a trend in increased mortality (but not significant) of those neonates which consumed IIM IgG as compared to those fed normal serum IgG as shown in Figure 3. This shows that the administration of virus with IIM IgG will increase insect mortality and can be an important strategy in the suppression of insect damage.

Ubiquity Of Mucins In Insect Species

T. ni mucin or IIM is an integral peritrophic membrane or matrix (PM) protein. IIM with its cysteine rich domains, apparently binds chitin to form a strong semipermeable structure which partitions ingested food and microbes from the midgut epithelium and may aid in digestion. The inventors examined the distribution of mucin (IIM) in different insect species.

Table 3.

Common name	Genus species	Family	Cross Reactivity with anti-IIM
Cabbage looper	<i>T. ni</i>	Noctuidae	yes
Armyworm	<i>Pseudaletia unipuncta</i>	Noctuidae	yes
Tobacco budworm	<i>Heliothis virescens</i>	Noctuidae	yes
Black cutworm	<i>Agrotis ipsilon</i>	Noctuidae	yes
Beet armyworm	<i>Spodoptera exigua</i>	Noctuidae	yes

Fall webworm	<i>Hyphantria cunea</i>	Arctiidae	yes
Banded woollybear	<i>Pyrrharctia isabella</i>	Arctiidae	yes
Imported Cabbageworm	<i>Pieris rapae</i>	Pieridae	?
Common white butterfly	<i>Pieris napi</i>	Pieridae	no
Silkworm	<i>Bombyx mori</i>	Bombycidae	yes
European corn borer	<i>Ostrinia nubilalis</i>	Pyralidae	yes
Monarch butterfly	<i>Danux plexippus</i>	Danidae	yes
Gypsy moth	<i>Lymantria dispar</i>	Lymantriidae	yes
Potato tuberworm	<i>Phthorimaea operculella</i>	Gelechiidae	yes
Diamondback moth	<i>Plutella xylostella</i>	Plutellidae	yes
House fly	<i>Musca domestica</i>	Muscidae	yes
Tarnished plant bug	<i>Lygus lineolaris</i>	Miridae	yes
Sweet potato whitefly	<i>Bemisia tabaci</i>	Aleyrodidae	yes
English grain aphid	<i>Sitobion avenae</i>	Aphididae	yes
American cockroach	<i>Periplaneta americana</i>	Blattidae	yes
German cockroach	<i>Blattella germanica</i>	Blattellidae	yes
Fruitfly	<i>Drosophila melanogaster</i>	Drosophilidae	?
Yellowfever Mosquito	<i>Aedes aegypti</i>	Culicidae	?
Fungus gnat	<i>Bradysia spp.</i>	Sciaridae	no
Colorado potato beetle	<i>Leptinotarsa decemlineata</i>	Chrysomelidae	no
Western spotted cucumber beetle	<i>Diabrotica undecimpunctata</i>	Chrysomelidae	no
Mealybug	<i>Planococcus citri</i>	Pseudococcidae	no

Insect midgut was dissected to remove the PM. PM proteins were solubilized in SDS sample buffer containing mercaptoethanol. Supernatants were subjected to SDS-PAGE, blotted onto nitrocellulose membranes, probed with a polyclonal anti-IIM antibody preparation, washed, and incubated in a secondary antibody labeled with alkaline phosphatase. Bands were visualized by the addition of NBT/BCIP solution to the blots.

Seventy-six percent of the insect species tested (16/21) possess protein or protein moieties which cross reacted with anti-IIM antibody. Table 1 lists the insect species tested for the presence of mucin. PMs were examined in all insects except for mealy bugs and sweet potato whitefly where the whole insect was used. Only midguts of Lygus bugs were extracted and examined for the presence of IIM.

Examination of blots showed the presence of strong to weak signals. Immunoreactive band development was strong in the tobacco budworm, fall armyworm, banded woollybear, armyworm and cabbage looper. The remainder (listed below) gave moderate, weak or no cross reactivity to anti-mucin antibody. Also, some insects had high molecular weight bands similar in size to *T. ni* IIM (denoted by asterix)

	Strong Band Development	Weak Reactivity
	* Tobacco budworm	*European corn borer
	* Fall armyworm	*Monarch butterfly
10	* Banded Woollybear	American cockroach
	* Armyworm	Beet armyworm
	* Cabbage Looper	
	Moderate Reactivity	No Reactivity
15	* Black cutworm	Imported cabbageworm
	* Gypsy moth	Mealybug
	House fly	Fungus gnat
	German cockroach	Colorado potato beetle
20	Tarnished plant bug	
	Diamondback moth	
	Potato tuberworm	
	Whitefly	

* = possess bands which are around 400 kD

These studies have demonstrated that mucin (IIM) or mucin-like PM proteins are present in a wide variety of insect species in 5 orders. These insects and possibly many other species may share common mechanisms which involve mucin or mucin like proteins which bind chitin thus permitting the formation of PM. It is interesting to note that a *Homopteran* and a *Hemipteran* possess discrete bands which cross-react with anti-IIM antibody. This is interesting observation since these insects may not produce a PM as found in other insects. Some investigators feel these insects may produce extracellular secretions that may be functional analogues to the chitinous PM. Based on our observations, there may exits in Homopterans and Hemipterans a protective barrier present which contains mucin-like proteins.

Two potential relevant applications exist to this work. First, the insects which cross react with anti-IIM may be sensitive to the PM degrading molecule enhancin.

Second, these same insect PMs may be susceptible to antibody binding which would reduce nutrient assimilation thus leading to a pre-reproductive growth or death.

Chitin Binding and its Potential as an Insecticidal Target

Plant lectins, which are carbohydrate binding proteins, have been tested for their insecticidal activity against many insect species and some show promise for use in transgenic plants. The mechanism for this anti-insect activity is not known but is believed to be mediated by lectin binding to chitin in the PM or by interacting with glycoproteins on the midgut epithelial cells. Wheat germ agglutinin (WGA) is a chitin specific lectin and others have shown that in the European corn borer, *Ostrinia nubilalis*, WGA could bind to the chitin in the midgut and interfered with PM formation. Such interference resulted in an altered and discontinuous PM structure, which allowed the food content to penetrate through the PM protective barrier. Our recent ultrastructural studies on the PM formation in *T. ni* larvae have shown that chitin is always co-localized with IIM in the midgut. These immunocytochemical studies showed that nascent PMs were initially delaminated as chitin containing fibrils from the anterior region of the midgut and subsequently, the major protein (IIM) was added to the PM matrix.

Calcofluor is a fluorescent dye with high chitin binding affinity. It has been utilized in studies on the formation of fungi and algal cell walls which are protective structures containing chitin and proteins. Calcofluor interferes with the cell wall formation by binding to nascent chitin molecules during cell wall formation, thus blocking chitin fibril assembly. Similar investigations on insect midgut chitin fibril formation using the chitin binding agent Calcofluor had not been approached until our recent studies were carried out. Our studies have shown that Calcofluor can be used to extract and solubilize chitin binding proteins from dissected *T. ni* PMs. These isolated proteins have high chitin binding properties and are normally not extractable from fully formed PMs by detergents or extreme pH conditions. Calcofluor fed to *T. ni* larvae completely inhibited and/or disrupted PM formation. We believe that this phenomenon

is due to the disruption of chitin fibril formation by the binding of Calcofluor to nascent chitin molecules as observed in other organisms.

This PM disruption/inhibition phenomenon was further verified in *Lymantria dispar*, *Pseudaletia unipuncta*, *Helicoverpa zea*, and *Hyphantria cunea*. Elegant studies with plant fungal systems which used dye compounds including Calcofluor showed that chitin biosynthesis and assembly was probably disrupted. We believe that binding of Calcofluor to the PM chitin blocked the interactions among chitin molecules and/or the binding between chitin and newly synthesized PM proteins, and severely interfered with PM formation. Feeding T ni larvae with an artificial diet containing 1% Calcofluor (a concentration used by most investigators) resulted in insect mortality and significantly slowed the growth of the treated larvae. As expected the disruption of PM formation by Calcofluor resulted in significantly increased baculovirus infections in the larvae.

This same phenomenon of increasing virus infection was first observed by others; however, the mechanism of action on the insect PM was not determined until now. Our studies on the effect of Calcofluor on PM formation has uncovered a unique mode of action of this chitin binding agent in the insect midgut. These findings confirm our hypothesis that targeting the chitin in the insect midgut by chitin binding peptides can affect PM formation or its properties, causing significant disruption of midgut physiology and function. If these chitin targeting molecules are shown to have possible insecticidal properties, the genes for chitin binding peptides will serve as new genetic tools for use in recombinant microorganisms and transgenic plants.

Our current studies have demonstrated that PM proteins strongly bind to the chitinous PM matrix and such binding is critical for the PM formation and its function. Sequence analyses of T ni IIM and other PM proteins have shown that these midgut proteins contain multiple putative chitin binding domains as follows:

Amino acid position (See SEQ. ID. NO. 3 & 4)

IIM region II-- amino acid 26 to 98

IIM region IVa- amino acid 243 to 315

IIM region IVb- amino acid 320 to 392

IIM region IVc- amino acid 408 to 478

IIM region VI

IIM 14--amino acid 695 to 757

5 IIM 22--amino acid 714 to 776

Nucleotide position(See SEQ. ID. NO. 1 & 2)

IIM region II

IIM 14--nucleotide 113 to 331

IIM 22--nucleotide 101 to 319

10 IIM region IVa

IIM 14--nucleotide 767 to 982

IIM 22--nucleotide 755 to 970

IIM region IVb

IIM 14--nucleotide 995 to 2013

15 IIM 22--nucleotide 983 to 2001

IIM region IVc

IIM 14-- nucleotide 1258 to 1471

IIM 22-- nucleotide 1246 to 1459

IIM region VI

20 IIM 14-- nucleotide 2120 to 2308

IIM 22-- nucleotide 2165 to 2353

To isolate these chitin binding domains, one can express T ni IIM in insect cells using a recombinant baculovirus. Construction of recombinant baculoviruses to express foreign proteins is a routine technique. To construct the recombinant
25 baculovirus, one clones the IIM cDNA into a baculovirus expression transfer vector which utilizes the polyhedrin gene promoter to express the IIM (e.g. pBlueBac4.5 from Invitrogen). Recombinant baculoviruses can be generated by cotransfection of insect cells with the constructed transfer vector and linearized Autographa californica nuclear polyhedrosis virus DNA (e.g. Bac-N-Blue AcN/fNPV DNA from Invitrogen). The IIM
30 can be expressed in the high recombinant protein producing cell line, HighFiveTM (Invitrogen). The suitability of the insect cell expression system for IIM expression can

be confirmed by assaying the chitin binding activity of the insect cell-expressed IIM to regenerated chitin. Briefly, insect cells infected with the recombinant AcN/fNPV are lysed with a non-ionic detergent, such as Triton X-100 and sonication. The cell lysate is clarified by centrifugation and incubated with regenerated chitin to let IIM bind to the chitin. The chitin/protein complexes are thoroughly washed with buffer and isolated by centrifugation. Chitin bound IIM are released with a SDS/B-mecaptoethanol sample buffer and subsequently analyzed by SDS-PAGE and Western blot analysis with an anti-IIM antiserum. A similar approach was used for a mosquito PM protein which was over expressed in insect cells and demonstrated to have chitin binding activity.

The chitin binding regions can be confirmed by a biochemical approach. T ni IIM can be over expressed in insect cells using a baculovirus expression vector and bound to regenerated chitin following the procedures described above. Following the binding reaction, the chitin/IIM complexes are washed with buffer to remove unbound IIM and contaminant proteins. Our current studies on isolated native T ni PM proteins have shown that these proteins have chitin binding activities and the proteins/chitin complexes are strongly bound and resistant to washing with stringent buffers (e.g. 20mM acetic acid or 1 %SDS). Controlled proteolysis with protease K of the chitin bound IIM is performed to selectively degrade non-chitin-binding regions of the IIM. Chitin bound fragments are isolated as protein/chitin complexes by centrifugation and subsequent washing with buffer and then solubilized with a SDS/ mecaptoethanol-containing sample buffer. The chitin bound fragments with an expected low molecular weight (chitin binding domains) are analyzed by SDS-PAGE (15% to 20% gels) to separate individual fragments. These fragments are subsequently isolated and subjected to N terminal protein sequencing by microsequence analysis. Based on the amino acid sequences derived from the chitin bound fragments, it is possible to design and synthesize peptides to test their chitin binding activities. Competitive binding assays of IIM to regenerated chitin with synthetic peptides as competitors can be conducted to determine the chitin binding activities of these synthetic peptides.

In order to determine the conserved amino acid residues important for chitin binding, one can design synthetic peptides based on published conserved sequences in

addition to the identified chitin binding domains above. Putative chitin binding sequences have been identified by sequence analysis in several PM proteins from different species (Elvin et al., 1996; Wang and Granados, 1997; Schorderet et al. 1998; Shen and Jacobs-Lorena, 1998) and these sequences are similar. Based on these
 5 reported sequences one can design synthetic peptides with a mutation to these conserved amino acid residues to identify and establish the conserved amino acid residues responsible for the strong chitin binding activity.

The chitin binding domains in IIM can also be identified by making deletions and mutations of the IIM gene. One can express truncated and mutated IIM proteins in
 10 insect cells using a baculovirus expression vector. The truncated IIM cDNA fragments are prepared using polymerase chain reactions (PCR) using oligonucleotide primers flanking the desired cDNA fragments. These primers are designed to contain suitable restriction enzyme digestion sites so that the amplified cDNA fragments can be easily cloned in frame into the expression vector. Truncated proteins are transiently expressed
 15 by transfecting insect cells (e.g. High FiveTM cells) with the expression vectors. Chitin binding activities of the expressed proteins will be assayed by their incubation with regenerated chitin followed by analyses of the chitin bound proteins by SDS-PAGE and Western blotting using an anti-IIM antiserum.

IIM fragments can be expressed in insect cells as intracellular proteins and be
 20 released from cells by solubilization with a nonionic detergent such as Triton X-100 and by sonication. The chitin binding activities of the expressed peptides are assayed by incubation of the cell lysates with regenerated chitin in an Eppendorf tube followed by washing of the chitin by centrifugation. Subsequently, the chitin bound peptides is analyzed by SDS-PAGE and Western blot analysis with an anti-IIM antiserum. If
 25 assays using whole cell lysates results in high cell protein background, one can construct an expression vector containing a secretion signal peptide at the N-termini of the peptides to be expressed. In such a way, one can obtain the expressed peptides from serum free cell culture medium, thereby minimizing contamination with cellular proteins. Alternatively, one can construct a vector containing a polyHistidine tag fused
 30 to the cDNA inserts. PolyHistidine fused peptides can be isolated using a metal-

charged agarose resin (e.g. Probond Metal Binding Resin from Invitrogen) before chitin binding assays are conducted.

One can use the fragments to identify and evaluate amino acid residues necessary for chitin binding activity by substitution of these candidate residues. Amino acid residue substitution is accomplished following site directed mutagenesis of the cloned cDNA fragments for chitin binding domains. Oligonucleotides containing a mutated site are generated and mutant clones are obtained using a site directed mutation kit (e.g. GeneEditor in vitro site-directed mutagenesis system from Promega). Mutated chitin binding domains are expressed in insect cells and their chitin binding activities are assayed. Such assays will identify specific residues necessary for chitin binding.

Identified chitin binding domains can be over-expressed as chitin binding peptides in E coli using an E coli expression vector, such as PRSET expression vector series (Invitrogen), to determine if E. coli expressed peptides have chitin-binding activities. The over expressed peptides carries a fused polyHistidine tag so that these chitin binding peptides can be easily isolated using nickel-charged agarose resin. Tests of chitin binding activities of E. coli expressed peptides are performed using the chitin binding assay described above. If the expressed peptides show chitin binding activities, this provide an efficient and economical system for production of these chitin binding peptides for use in biological studies.

Chitin binding peptides can also be over expressed in an eukaryotic system using insect cells and recombinant baculovirus vectors. cDNA fragments coding for chitin binding peptides are cloned into a baculovirus expression transfer vector which utilizes the polyhedrin gene promoter to express polyHistidine fusion proteins (E.g. pBlueBacHis2 series from Invitrogen). Recombinant baculoviruses are generated as described above. Expressed chitin binding peptides are isolated using a nickel-charged agarose resin.

Anti-IIM Antibody and Serum Production

- To isolate an Anti-IIM antibody serum, IIM is purified by solubilizing *T.ni* PM in SDS buffer containing mercaptoethanol according to the extraction procedure described in the literature (Wang and Granados, *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 6977-6982). The solubilized PM proteins are subjected to SDS-PAGE and bands are visualized by copper staining. The band containing IIM is cut from the gels, destained and electro-eluted. To help remove SDS from proteins, elutant will be loaded on a column containing AG-1-X2 resin (Biorad). The elutant is lyophilized leaving the concentrated protein. Generally, 1000 PMs yields 30 µg of purified IIM.
- 10 To obtain large amounts of serum goats are used and inoculated with IIM protein antigen. A similar technique has been used by Casu *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **94**, 8939-8944). Tellam and Eisemann's injection protocol is used (*Int. J. Parasitol.*, **28**, 439-450) where IIM is first mixed in Freund's incomplete adjuvant and then equal portions are injected intramuscular into each rear leg. A second injection is
- 15 given 1 month later in the neck region. The goats are bled prior to each injection and 2 weeks after the first injection.

- IIM can also be isolated from insect frass by collecting excreted PMs for the isolation of PM protein. *T.ni* larvae are reared to the fifth instar on a high wheat germ diet and then placed on diet containing sucrose and agar. Feeding insects on this diet
- 20 should clear their alimentary canals of ingested high wheat germ diet and produce PMs relatively clean of dietary protein. PMs are collected, IIM solubilized and purified as described above.

- To generate antibodies to chitin binding domains of PM proteins, chitin binding peptides are expressed using a baculovirus expression vector in High FiveTM insect
- 25 cells for optimum expression of peptides as described above. Polyclonal antibodies are produced in New Zealand White rabbits by injecting them with a total of 25-50 µg of purified peptide. Preimmune serum is collected and used for control experiments. An antigen-capture ELISA is performed to determine the concentration of the total IgG in the original sera. To create a monoclonal antibody the antigen would be injected into a

mouse and a hybridoma is created by well known methods. The gene encoding the antibody can then be isolated and used to transfect plants.

The antigen for any of the above can also be recombinant protein, which would be most useful if the desire was to target specific chitin binding sites. There are five
 5 chitin binding sites in IIM and they are depicted in Figure 4. Anyone of these regions could be expressed in an appropriate vector, e.g. baculovirus expression system, to create antibodies that bind specifically to these regions.

Transgenic Organisms Expressing anti IIM-IgG

10 The present invention includes a transgenic plant that express IIM-IgG. Since the immunotherapeutic potential of antibodies produced in plants has been demonstrated in a number of cases, we believe that using peritrophic matrix IIM-specific Ab in plants could be used as immunocontrol strategy for control of insect pests. The concept of using PM Ab to control insect pest has been established in the
 15 case of insects that are animal pests. Researchers in Australia have shown that PM proteins injected into sheep produce antibodies that interfere with the growth or even kill the fly pest, *Lucilia cuprina* that causes cutaneous myiasis in the sheep, a conditions that causes over 200 million dollars in losses per year. These researcher provided evidence that the Ab were able to interfere with the porosity of the fly PM and
 20 interfered with the normal digestive processes of the insect. They speculated that this type of approach could be used in plants to control insects, however, provided not guidance as to how to accomplish such and approach.

A gene encoding an antibody that binds IIM or a fragment thereof may be used to transfect a microbial host. Microorganism hosts may be selected which are known to
 25 occupy the environment that the insect larval pest occupies. Such microorganisms include bacteria, algae, and fungi. A number of ways are known in the art for introducing a such a gene into the microorganism host under conditions which allow for stable maintenance and expression of the gene. For example, expression cassettes can be constructed which include the DNA constructs of interest operably linked with

the transcriptional and translational regulatory signals for expression of the DNA constructs, and a DNA sequence homologous with a sequence in the host organism, whereby integration will occur, and/or a replication system which is functional in the host, whereby integration or stable maintenance will occur.

- 5 A transgenic plant expressing IIM-IgG can be constructed using available techniques for insertion of cDNA encoding an antibody to IIM into a plant genome. Referring figure 1, the regions designated II, IV and VI are chitin binding regions. Antibodies that bind to any of the regions would block chitin binding and provide the desired effect.

- 10 Thus the preferred first step in developing a transgenic plant is to raise one or more antibodies to the chitin binding regions. However, it could be desirable to raise an antibody that bound to a non-chitin binding region of the protein so that the chitin binding function of the protein remained intact. The antibody could then block pores in the PM but not disrupt PM formation.

- 15 Technology for using transgenic plants to express such antibodies is known in the art. Specifically, U.S. Patent No 5,686,600 teaches the production of antibodies that bind to insect midgut tissue and the use of such antibodies. The teaching of this patent are incorporated herein by reference. The novel IIM protein discovered by the applicants is an excellent target protein for the antibody binding.

- 20 An antibody, monoclonal antibody, or fragment thereof is said to be capable of binding a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody, monoclonal antibody, or fragment thereof. The term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as fragments or binding regions or domains thereof which are capable of
- 25 binding to the regions described above. Such fragments are typically produced by proteolytic cleavage, such as papain or pepsin, but can be produced through the application of recombinant DNA technology or through synthetic chemistry.

Methods for the preparation of the antibodies of the present invention are generally known in the art. For example, see Antibodies, A Laboratory Manual, Ed

Harlow and David Lane (eds.) Cold Spring Harbor Laboratory, N.Y. (1988), as well as the references cited therein. Standard reference works setting forth the general principles of immunology include: Klein, J. *Immunology: The Science of Cell-Noncell Discrimination*, John Wiley & Sons, N.Y. (1982); Dennett, R., et al. *Monoclonal Antibodies, Hybridoma: A New Dimension in Biological Analyses*, Plenum Press, N.Y. (1980); and Campbell, A. "Monoclonal Antibody Technology," In *Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13, Burdon et al. (eds.), Elsevier, Amsterdam (1984). See also, U.S. Pat. Nos.: 4,609,893; 4,713,325; 4,714,681; 4,716,111; 4,716,117; and 4,720,459.

The antibodies which possess the desired binding specificity can be used as a source of messenger RNA for cloning of the cDNA for the particular monoclonal antibody. Antibody genes can be cloned from hybridoma cells using primers to conserved DNA sequences within the constant regions and the framework regions of the variable regions. This can be followed by amplification of the DNA for cloning using the polymerase chain reaction (PCR). A database of mouse heavy chain and light chain sequences compiled by Kabat et al. has been successfully used to generate both isotype specific and degenerate prim for cloning antibody genes (Kabat, E. A. et al., 1987, U.S. Dept Health and Human Services, U.S. Government Printing Offices and Jones, S. T. and Bendig, M., 1991, *Bio/technology* 9:88-89). Additionally, there is a wealth of knowledge concerning the cloning of smaller fragments of antibodies which possess the binding properties of the original antibody.

The cloned DNA can then be sequenced by methods known in the art. See, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd. Edition, Cold Spring Harbor Laboratory Press, N.Y. (1989) vol. 1-3, and the references cited therein. From the nucleic acid sequence, the protein sequence of the binding region from the selected MAb can be deduced.

The antibodies and monoclonal antibodies of the invention find use in the production of hybrid toxin molecules. By "hybrid toxin molecules" or "hybrid toxins" is intended, fusion proteins or immunotoxins, which comprise a monoclonal antibody or antibody fragment operably linked to a toxin moiety and which is capable of binding

- to the gut of an insect. That is, when linked, the monoclonal antibody or antibody fragment retains its binding properties and the toxin moiety retains its cytotoxic properties. DNA sequences encoding the toxin moiety of the hybrid toxins are known in the art. See, Lamb et al. (1985) *Eur. J. Biochem.* 148:275-170 (Ricin); Gray et al. (1984) *PNAS* 81:2645-2649 (*Pseudomonas* toxin DNA Sequence); Hindley and Berry (1988) *Nuc. Acids Res.* 16:4168 (*B. sphaericus* toxin gene); Bauman et al. (1988) *J. Bacteriol* 170:2045-2050, Bauman et al. 1987) *J. Bacteriol* 169:4061-4067, Berry and Hindley (1987) *Nucleic Acids Res.* 15:5891, Berry et al. (1989) *Nucleic Acids Res.* 17:7516 (*B. sphaericus*); WO 9309130-A (gelonin); EP 466222-A, U.S. Pat. No. 5,128,460 (ribosome-activating protein); EP 412911-A (barnase); Heernstadt et al. (1987) *Gene* 57:37-46 (cryIIIA); Brizzard and Whiteley (1988) *Nucleic Acids Res* 16:2723-2724 (cryIB); and Geiser et al. (1986) *Gene* 48:109-118 (cryIA(b)). See also Porter et al. (1993) *Microbiological Reviews* 57:838-861; Hofte and Whiteley (1989) *Microbiological Reviews* 53:242-255
- 15 The antibody genes can be cloned and expressed in plants in such a manner that functional antibodies are assembled. See, for example, Hiatt et al. (1989) *Nature* 342:76-78 During et al. (1990) *J. Plant Molecular Biology* 15:281-293 and PCT Application WO 91/06320. Levels of bivalent antibody expression have been reported to be as high as 1% of the soluble protein in tobacco. It is recognized that as well as antibody molecules, antibody fragments such as Fab and Fv fragments, can be utilized. 20 The use of these antibody fragments provides the option of reducing the insect specific binding domain derived from a MAb to a very small size.
- 25 The genes can be optimized for enhanced expression in plants. See, for example EPA 0359472; EPA 0385962; WO 91/16432; Perlak et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:3324-3328; and Murray (1989) *Nucleic Acids Research* 17:477-498. In this manner, the genes can be synthesized utilizing plant preferred codons. That is, the preferred codon for a particular host is the single codon which most frequently encodes that amino acid in that host. Synthetic genes could also be made based on the distribution of codons a particular host uses for a particular amino acid. Following this

approach, the nucleotide sequences can be optimized for expression in any plant and all or any part of the gene sequence may be optimized or synthetic.

- Methods for the transformation of plant cells and regeneration of transformed plants are well known in the art. Generally, for the introduction of foreign DNA into plants Ti plasmid vectors have been utilized as well as direct DNA uptake, liposomes, electroporation, micro-injection, and the use of microprojectiles. Such methods have been published. See, for example, Guerche et al., (1987) *Plant Science* 52:111-116; Neuhauser et al., (1987) *Theor. Appl. Genet.* 75:30-36; Klein et al., (1987) *Nature* 327:70-73; Howell et al., (1980) *Science* 208:1265; Horsch et al., (1985) *Science* 227:1229-1231; DeBlock et al., (1989) *Plant Physiology* 91:694-701; *Methods for Plant Molecular Biology* (Weissbach and Weissbach, eds.) Academic Press, Inc. (1988); and *Methods in Plant Molecular Biology* (Schuler and Zielinski, eds.) Academic Press, Inc. (1989). See also, EPA 0193259 and EPA 0451878A1. It is understood that the method of transformation will depend upon the plant cell to be transformed.
- The components of an expression cassette containing the sequence of interest may be modified to increase expression in the plant or plant cell. For example, truncated sequences, nucleotide substitutions or other modifications may be employed. See, for example Perlak et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:3324-3328; Murray et al. (1989) *Nucleic Acids Research* 17:477-498; and WO 91/16432. The construct may also include any other necessary regulators such as terminators, (Guerineau et al., (1991), *Mol. Gen. Genet.*, 226:141-144; Proudfoot, (1991), *Cell*, 64:671-674; Sanfacon et al., (1991), *Genes Dev.*, 5:141-149; Mogen et al., (1990), *Plant Cell* 2:1261-1272; Munroe et al., (1990), *Gene*, 91:151-158; Ballas et al., (1989), *Nucleic Acids Res.*, 17:7891-7903; Joshi et al., (1987), *Nucleic Acid Res.*, 15:9627-9639); plant translational consensus sequences (Joshi, C. P., (1987), *Nucleic Acids Research*, 15:6643-6653), introns (Luehrsen and Walbot, (1991), *Mol. Gen. Genet.*, 225:81-93) and the like, operably linked to the nucleotide sequence. For tissue specific expression, the nucleotide sequences of the invention can be operably linked to tissue specific promoters.

Accordingly, it is to be understood that the embodiments of the invention herein described are merely illustrative of the application of the principles of the invention.

Reference herein to details of the illustrated embodiments are not intended to limit the scope of the claims, which themselves recite those features regarded as essential to the

5 invention.

SEQUENCE LISTING

- 5 (1) GENERAL INFORMATION:
- (i) APPLICANT: Granados, Robert R
Wang, Ping
- 10 (ii) TITLE OF INVENTION: A Novel Invertebrate Intestinal Mucin
cDNA and Related Products and Methods
- (iii) NUMBER OF SEQUENCES: 4
- 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Brown, Pinnisi & Michaels, P.C.
(B) STREET: 118 North Tioga Street
(C) CITY: Ithaca
(D) STATE: NY
20 (E) COUNTRY: USA
(F) ZIP: 14850
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
25 (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
30 (B) FILING DATE: 19-APR-1999
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
35 (A) APPLICATION NUMBER: US 09/103,429
(B) FILING DATE: 24-JUN-1998
- (viii) ATTORNEY/AGENT INFORMATION:
40 (A) NAME: Michaels, Christopher A
(B) REGISTRATION NUMBER: 34,390
(C) REFERENCE/DOCKET NUMBER: BTI-39-CIP
- (ix) TELECOMMUNICATION INFORMATION:
45 (A) TELEPHONE: (607) 256-2000
(B) TELEFAX: (607) 256-3628
- (2) INFORMATION FOR SEQ ID NO:1:
- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2455 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
55 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- 60 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Trichoplusia ni*

(F) TISSUE TYPE: Peritrophic Membrane

(vii) IMMEDIATE SOURCE:

(B) CLONE: IIM14

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15	GTAACGTTAA GTGAAAAGAA TAACCAGCGA ACAAGTTATG ATAAAGACCC TCCTATTCTC	60
	GACGGCCCTC GGGCTCGTCG CCGCGCGTCC TGAAGTCAGC GACGCGGAGA AGAACCCGCG	120
	TCTCCACGAG CCGCACCCAG ACTGCCCTCC CGCTGAGCAG CACTGGCTCC TGCCTCACGA	180
20	ATACGACTGC ACCAAGTTCT ACTACTGTGA ATATGGTCTC AAGTTCATCG CACCGAGAGA	240
	CTGTGCTCTC GGTACCGAAT TCAAGTTCTC CGCTCAGACT TGTGTTCAAG CCGCTTAGAC	300
25	CGGATGACCC CTGCCAGGAC CTCCAGCTGA GACAACCCAG GCCCCAGCAA CAACTCAGGC	360
	CCCAACAACC ACCCAGGCCC CAACCCACAAC TACTCAGGCC CCTACTACAA CCAACCAGGC	420
	CCCAACCACA ACCACCCAGG CCCCAACCAC CACCCAGGCC CCAACCACCA CCCAGGCCCC	480
30	AACTACCACT CAGGCCCCCTA CTACTACCCAC TCAGGCCCCA ACCACAACCA CTCAGGCCCC	540
	TACCACAACC ACCCAGGCCC CAACCCACCAC CCAGGCCCCA ACTACCAACC AGGCCCCAAC	600
	TACCACTCAG GCCCAACTA CAATCAACCA GGCTGCAACT ACCCCGGCGG CAACTACCCC	660
35	GGCGCAACT ACCCCGGCGG CAACTACCCC TGCGCGGACA ACCCCGGCTG CAACTACCCC	720
	AGGTGTTCTC GCACCCACTT CAGCCCCAGT CTGGCCCCCG ATCTGTGAAC TGTGTCCCAA	780
40	TGGTGGCCCA GCTGACTTCG ACATCCACTT GTTGATTCCC CACGACAAGT ACTGCAACCT	840
	CTTCTACCAG TGCTCCAACG GTTACACCTT CGAACAGAGG TGCCCTGAGG GACTCTACTT	900
	CAACCCCTAC GTCCAGCGCT GCGACTCTCC TGCTAACGTT GAATGCGAGC GCGAAATCAG	960
45	CCCCGCACCC CCAGTCACAG AAGGCAACGA AGACGAAGAC ATTGACATCG GAGACCTCCT	1020
	CGACAATGGA TGCCCCAGCTA ACTTCGAAAT CGACTGGCTC TTGCCCCACG GAAACCGTTG	1080
50	CGACAAGTAT TACCACTGCG TCCACGATAA CTTGGTAGAG AGGCGTTGTG GAGCCGGCAC	1140
	CCACTTCAGT TTTGAACTTC AGCAATGTGA CCACATCGAG CTCGTGTGCT GCACCTCCCC	1200
	CGCGCGGAGG AGCGAAGAAG TTGACGTGCA CGAGGATGCC TGCACCGGCT GGTACTGCCC	1260
55	CAGCGAACCC ATTGAATGGG AGCCCCCTCCC CAACGGCTGC CCTGCCGACT TCAGCATCGA	1320
	CCACCTCCTC CCCACAGAGA GCGACTGCGG CCAGTATCTA CAGTGTGTCC ATGGACAGAC	1380
60	TATCGCAAGA CTTGCCCCGT GAAACCTGCA CTTAGTCTCT GCCACACAGT CCTGTGAGTC	1440
	TCCTGTGACC GCTGGTTGCC AAGTTTTCGA GTGCGATTCT GACAACAGT GCACATCGAC	1500
	TGCTGCCCGG ACAGCTGCTC CAACGGCTGC CCCAACGGCT GCCCAACGCG CTGCCCCAAC	1560

TGCCGACCCC TCCACCGTGG TCCCACCTGC AACGCCACCC GCAACTGCAG CCCCACTCCC 1620
 5 ACCTACAACC GCAATTCCTA CTCGGGCCCC CACCGCTGCC CCCACGCGAG CTCCTACTAC 1680
 TGCTGCCCTT GAATCCCAA CCACTGTCAC AGTACCACCT ACTGCTGCTC CCACGCGAGC 1740
 CCTACTACT GCTGTCCCTG AAATCCCAAT CACTGTCACA TCAGCGCCTA CCGCTGCCCC 1800
 10 CACCGCTGCC CCCACGCGAG CCCCACCGCG AGCCCTACT ACTGCTGTCC CAGAAATCCC 1860
 AACTACTGTC ACATCACCAC CTACTGCTGC CCCCACTACC GCAGCACCTG CCCCCAACAC 1920
 CACAGTCACT GTACCACCCA CTGTGCCCCC TACTACGCGA GCACCTGCCC CCAACACCAC 1980
 15 AGTCACTGTA CCACCCACTG CTGCCCCCAC TGCAGTCCC CCTACGCTCG CACATGCACC 2040
 CAACACCACA GCTGCCCGGG TAACTACAAC CAGCGCACCA GCTACCACAC CTGAAGATGA 2100
 20 TGACATCGAC CCCCTCTCC CCAACGAGCC CATCAACCTT TGGCTTGAAG AATGCAACGT 2160
 TTTCCTCTGG GCTCAGCTG ACTGCGACAA ATACTGGGTC TGTGACGGCA ACAACCAAGT 2220
 CCTGGTGGTT TGCTCTGAGG GTCTCCAGTT CAACCCCACT ACTAAGACCT GTGACTTCGC 2280
 25 TTGCAACGTC GGTTCGCTGA GGAGCAACAT TCAGATGTCT GAAAGCTAGC AAGGAGTCCA 2340
 GGTCTTCATC CCATGGAACA AACTAGATGA AGACATCAGA CAGCGCTGTA ACTTTAGATT 2400
 30 GTAAACCTAC TTAAATTAAT GAAGGTTTGT TTTTAAAAAA AAAAAAAAAA AAAAA 2455

(2) INFORMATION FOR SEQ ID NO:2:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2821 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: not relevant
 40 (ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 45 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Trichoplusia ni*
 50 (D) DEVELOPMENTAL STAGE: larva
 (F) TISSUE TYPE: peritrophic membrane

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAAAGAATA ACCAGCGAAC AAGTTATGAT AAAGACCTC CTATTCTGTA CGGCCCTCGG 60
 GCTCGTCGCC GCGGTCCTG AAGTCAGCGA CGCGGAGAAG AACCCGCTC TCACGAGCC 120
 60 GCACCCAGAC TGCCCTCCG CTGAGCAGCA CTGGCTCCTG CCTCACGAAT ACGACTGCAC 180
 CAAGTTCTAC TACTGTGAAT ATGGTCTCAA GTTCATCGCA CGAGAGACT GTGCTCCTGG 240

	TACCGAATTC	AAGTTCTCG	CTCAGACTTG	TGTTCAAGCC	GCTTTAGCCG	GATGCACCTT	300
	GCCAGGACCT	CCAGCTGAGA	CAACCCAGGC	CCCAGCAACA	ACTCAGGCCC	CAACAACCCAC	360
5	CCAGGCCCCA	ACCACAATA	CTCAGGCCCC	TACTACAACC	ACCCAGGCCC	CAACACAAC	420
	CACCCAGGCC	CCAACCACCA	CCCAGGCCCC	AACCACCACC	CAGGCCCAA	CTACCCTCA	480
10	GGCCCCCTACT	ACTACCCTC	AGGCCCCAAC	CACAACCACT	CAGGCCCTCA	CCACAACCCAC	540
	CCAGGCCCCA	ACCACCACCC	AGGCCCCAAC	TACCACCAG	GCCCCAATA	CCACTCAGGC	600
	CCCACTACA	ATCACCAGG	CTGCAACTAC	CCGGCCGCA	ACTACCCCG	CCGCAACTAC	660
15	CCGGCCGCA	ACTACCCCTG	CCGGCAAC	CCCCGCTGCA	ACTACCCAG	GTGTCTCTGC	720
	ACCCACTTCA	GCCCCAGTCT	GGCCCCGAT	CTGTGAATG	TTGCCCAATG	GTGTCCAGGC	780
20	TGACTTCGAC	ATCCACTTGT	TGATTCCCA	CGACAAGTAC	TGCAACTCTT	TCTACCAGTG	840
	CTCCAACGGT	TACACTTTCG	AACAGAGGTG	CCCTGAGGGA	CTCTACTTCA	ACCCCTACGT	900
	CCAGCGCTGC	GACTCTCTCTG	CTAACGTTGA	ATGGAGCGGC	GAAATCAGCC	CCGCAACCCCC	960
25	AGTCACAGAA	GGCAACGAAG	ACGAAGACAT	TGACATCGGA	GACCTCCTCG	ACAATGGATG	1020
	CCAGCTAAC	TTGGAATCG	ACTGGCTCTT	GCCCCACGGA	AACGTTGCG	ACAAGTATTA	1080
30	CCAGTGGCTG	CACGGTAACT	TGGTAGAGAG	GCGTTGTGGA	GCCGCGACCC	ACTTCAGTTT	1140
	TGAACCTTCAG	CAATGTGACC	ACATCGAGCT	CGTTGGCTGC	ACCTTCCCG	GCGGGAGAG	1200
	CGAAGAAGTT	GACGTCGACG	AGGATGCCTG	CACGGCTGG	TACTGCCCA	CGGAACCCAT	1260
35	TGAATGGGAG	CCCTCCCCA	ACGGCTGCC	TGCCGACTTC	AGCATCGACC	ACCTCTCCC	1320
	CCACGAGAGC	GACTGCGGCC	AGTATCTACA	GTGTGTCCAT	GGACAGACTA	TGCAAGACC	1380
40	TTGCCCTGGA	AACCTGCACT	TCAGTCTCTGC	CACACAGTCC	TGTGAGTCTC	CTGTGACCGC	1440
	TGGTTGCCAA	GTTTTCGAGT	GCGATTCTGA	CAACCACTGC	ACATCGAGTG	CTGCCCGGAC	1500
	AGCTGTCTCCA	ACGGCTGCC	CAACGGCTGC	CCCAACGGCT	GCCCCAATG	CCGCAACCTC	1560
45	CACCGTGGTC	CCACTGCA	CGCCACCCGC	AACCTGCAGC	CCAGTCCAC	CTACAACCGC	1620
	AATTCTACT	CCGGCCCCCA	CCGTGCCCC	CACCGCAGCT	CCTACTACTG	CTGCCCTGTA	1680
50	ATCCCCAACC	ACTGTCAAG	TACCACCTAC	TGCTGTCTCC	ACCGAGCCCC	CTACTACTGC	1740
	TGTCTCTGAA	ATCCCAATCA	CTGTCAATC	AGCGCTACC	GCTGCCCA	CCGTGCCCC	1800
	CACCGCTGCC	CCACCGCAG	CCCTACTAC	TGCTGTCCA	GAAATCCCA	CTACTGTAC	1860
55	ATCACCACT	ACTGTCTCCC	CCACTACCG	AGCACTGCC	CCCAACCA	CAGTCACTGT	1920
	ACCACCCACT	GCTGCCCTA	CTACCGCAGC	ACCTGTCTCC	AACCAACAG	TGACTGCACC	1980
60	ACCCACCGCA	CCCCCTACTA	CCGAGCACC	TGCCCCAAC	ACCACAGTCA	CTGTACCACC	2040
	CACCTGTGCC	CCCACTGCAG	CTCCCCCTAC	CGTGCAGCT	GCAACCACA	CCACAGCTGC	2100
	CCCGTTAACT	ACAACCGAGC	CACCAGCTAC	CACACCTGAA	GATGATGACA	TGCAACCCCC	2160

TCTCCCCAAC GACCCCATCA ACCCTTGGGT TGAAGAATGC AACGTTTTGC CTTGGGCTCA 2220
 CGCTGACTGC GACAAATACT GGGTCTGTGA CGGCAACAAC CAACTCCTGG TGGTTTGCTC 2280
 5 TGAGGGTCTC CAGTTCACCC CCACTACTAA GACCTGTGAC TTCGCTTGCA ACGTCGGTTG 2340
 CGTGAGGAGC AACATTGAGA TGCTGAAAG CTACGAAGGA GTCCAGGTCT TCATCCCATG 2400
 GAACAACTA GATGAAGACA TCAGACAGGC GCTGAACCTT GAGTTGTAAA CCTACTTAAA 2460
 10 TTAATGAAGG TTTTGTTTTA TTTTGTGAGT ATTATTCCAA TGGGCGGGAA AGTCCGCCAT 2520
 TATTGGGTCT TGCCAGTTT GAGGAAACCT TTTTTTTAC TACCAACATT CTTGTGAACC 2580
 15 CATATTTATT ACGTATTAAA CATCGTGATT TGAACAAAGT TACATGATT TTTCATTAA 2640
 TTGAACAAT TTATGTTGTT TTTGTTCTCA TTAATATCA AATATCATT TCGAACTGG 2700
 CAATTTTGA TTGAATAAT CAACAAATGG TTAAGAAAAA AAACGATTC TTAATAATGT 2760
 20 ATTTATTATA AAATGTGTAA ATAAATATAC AAATTAGCAT TTAACAAAAA AAAAAAAA 2820
 A 2821

25 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 788 amino acids
 (B) TYPE: amino acid
 30 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

35 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Trichoplusia ni*
 40 (F) TISSUE TYPE: peritrophic membrane

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ile Lys Thr Leu Leu Phe Leu Thr Ala Leu Gly Leu Val Ala Ala
 1 5 10 15

50 Arg Pro Glu Val Ser Asp Ala Glu Lys Asn Pro Ala Leu His Glu Pro
 20 25 30

His Pro Asp Cys Pro Pro Ala Glu Gln His Trp Leu Leu Pro His Glu
 35 40 45

55 Tyr Asp Cys Thr Lys Phe Tyr Tyr Cys Glu Tyr Gly Leu Lys Phe Ile
 50 55 60

60 Ala Pro Arg Asp Cys Ala Pro Gly Thr Glu Phe Lys Phe Ser Ala Gln
 65 70 75 80

Thr Cys Val His Ala Ala Leu Ala Gly Cys Thr Leu Pro Gly Pro Pro
 85 90 95

	Ala	Glu	Thr	Thr	Gln	Ala	Pro	Ala	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr
					100				105					110		
5	Gln	Ala	Pro	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Thr	Gln	Ala	
		115					120					125				
	Pro	Thr	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr
		130					135					140				
10	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Thr	Gln	Ala
		145					150					155				160
	Pro	Thr	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Thr	Gln	Ala	Pro	Thr
							165					170				175
15	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Gln	Ala	Pro	Thr	Thr	Thr	Gln	Ala
			180						185						190	
20	Pro	Thr	Thr	Ile	Thr	Gln	Ala	Ala	Thr	Thr	Pro	Ala	Ala	Thr	Thr	Pro
				195					200					205		
	Ala	Ala	Thr	Thr	Pro	Ala	Ala	Thr	Thr	Pro	Ala	Ala	Thr	Thr	Pro	Ala
			210				215						220			
25	Ala	Thr	Thr	Pro	Gly	Val	Pro	Ala	Pro	Thr	Ser	Ala	Pro	Val	Trp	Pro
		225				230					235					240
	Pro	Ile	Cys	Glu	Leu	Leu	Pro	Asn	Gly	Cys	Pro	Ala	Asp	Phe	Asp	Ile
						245				250					255	
30	His	Leu	Leu	Ile	Pro	His	Asp	Lys	Tyr	Cys	Asn	Leu	Phe	Tyr	Gln	Cys
				260					265					270		
35	Ser	Asn	Gly	Tyr	Thr	Phe	Glu	Gln	Arg	Cys	Pro	Glu	Gly	Leu	Tyr	Phe
			275					280						285		
	Asn	Pro	Tyr	Val	Gln	Arg	Cys	Asp	Ser	Pro	Ala	Asn	Val	Glu	Cys	Asp
			290				295						300			
40	Gly	Glu	Ile	Ser	Pro	Ala	Pro	Pro	Val	Thr	Glu	Gly	Asn	Glu	Asp	Glu
						310					315					320
	Asp	Ile	Asp	Ile	Gly	Asp	Leu	Leu	Asp	Asn	Gly	Cys	Pro	Ala	Asn	Phe
						325				330					335	
45	Glu	Ile	Asp	Trp	Leu	Leu	Pro	His	Gly	Asn	Arg	Cys	Asp	Lys	Tyr	Tyr
				340					345					350		
50	Gln	Cys	Val	His	Gly	Asn	Leu	Val	Glu	Arg	Arg	Cys	Gly	Ala	Gly	Thr
			355				360						365			
	His	Phe	Ser	Phe	Glu	Leu	Gln	Gln	Cys	Asp	His	Ile	Glu	Leu	Val	Gly
							375					380				
55	Cys	Thr	Leu	Pro	Gly	Gly	Glu	Ser	Glu	Glu	Val	Asp	Val	Asp	Glu	Asp
						390					395					400
	Ala	Cys	Thr	Gly	Trp	Tyr	Cys	Pro	Thr	Glu	Pro	Ile	Glu	Trp	Glu	Pro
						405					410				415	
60	Leu	Pro	Asn	Gly	Cys	Pro	Ala	Asp	Phe	Ser	Ile	Asp	His	Leu	Leu	Pro
						420				425				430		
	His	Glu	Ser	Asp	Cys	Gly	Gln	Tyr	Leu	Gln	Cys	Val	His	Gly	Gln	Thr

	435		440		445
	Ile Ala Arg Pro Cys Pro Gly Asn Leu His Phe Ser Pro Ala Thr Gln				
	450		455		460
5	Ser Cys Glu Ser Pro Val Thr Ala Gly Cys Gln Val Phe Glu Cys Asp				
	465		470		475
					480
10	Ser Asp Asn Gln Cys Thr Ser Thr Ala Ala Pro Thr Ala Ala Pro Thr				
			485		490
					495
	Ala Ala Pro Thr Ala Ala Pro Thr Ala Ala Pro Thr Ala Ala Pro Ser				
			500		505
					510
15	Thr Val Val Pro Pro Ala Thr Pro Pro Ala Thr Ala Ala Pro Val Pro				
			515		520
					525
	Pro Thr Thr Ala Ile Pro Thr Pro Ala Pro Thr Ala Ala Pro Thr Ala				
			530		535
					540
20	Ala Pro Thr Thr Ala Ala Pro Glu Ser Pro Thr Thr Val Thr Val Pro				
			545		550
					555
					560
25	Pro Thr Ala Ala Pro Thr Ala Ala Pro Thr Thr Ala Val Pro Glu Ile				
			565		570
					575
	Pro Ile Thr Val Thr Ser Ala Pro Thr Ala Ala Pro Thr Ala Ala Pro				
			580		585
					590
30	Thr Ala Ala Pro Thr Ala Ala Pro Thr Thr Ala Val Pro Glu Ile Pro				
			595		600
					605
	Thr Thr Val Thr Ser Pro Pro Thr Ala Ala Pro Thr Thr Ala Ala Pro				
			610		615
					620
35	Ala Pro Asn Thr Thr Val Thr Val Pro Pro Thr Ala Ala Pro Thr Thr				
			625		630
					635
					640
40	Ala Ala Pro Ala Pro Asn Thr Thr Val Thr Val Pro Pro Thr Ala Ala				
			645		650
					655
	Pro Thr Ala Ala Pro Pro Thr Val Ala His Ala Pro Asn Thr Thr Ala				
			660		665
					670
45	Ala Pro Val Thr Thr Thr Ser Ala Pro Ala Thr Thr Pro Glu Asp Asp				
			675		680
					685
	Asp Ile Asp Pro Pro Leu Pro Asn Asp Pro Ile Asn Pro Cys Val Glu				
			690		695
					700
50	Glu Cys Asn Val Leu Pro Trp Ala His Ala Asp Cys Asp Lys Tyr Trp				
			705		710
					715
					720
55	Val Cys Asp Gly Asn Asn Gln Val Leu Val Val Cys Ser Glu Gly Leu				
			725		730
					735
	Gln Phe Asn Pro Thr Thr Lys Thr Cys Asp Phe Ala Cys Asn Val Gly				
			740		745
					750
60	Cys Val Arg Ser Asn Ile Gln Met Ser Glu Ser Tyr Glu Gly Val Gln				
			755		760
					765
	Val Phe Ile Pro Trp Asn Lys Leu Asp Glu Asp Ile Arg Gln Ala Leu				
			770		775
					780

Asn Phe Glu Leu
785

- 5 (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 807 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- 15 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- 20 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Trichoplusia ni*
 (F) TISSUE TYPE: peritrophic membrane
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
- 25 Met Ile Lys Thr Leu Leu Phe Leu Thr Ala Leu Gly Leu Val Ala Ala
 1 5 10 15
- 30 Arg Pro Glu Val Ser Asp Ala Glu Lys Asn Pro Ala Leu His Glu Pro
 20 25 30
- His Pro Asp Xaa Pro Pro Ala Glu Gln Xaa Xaa Leu Leu Pro Xaa Glu
 35 35 40 45
- 35 Tyr Asp Cys Thr Lys Phe Tyr Tyr Cys Glu Tyr Gly Leu Lys Phe Ile
 50 55 60
- Ala Pro Arg Asp Cys Ala Pro Gly Thr Glu Phe Lys Phe Ser Ala Gln
 40 65 70 75 80
- Thr Cys Val His Ala Ala Leu Ala Gly Cys Thr Leu Pro Gly Pro Pro
 85 90 95
- 45 Ala Glu Thr Thr Gln Ala Pro Ala Thr Thr Gln Ala Pro Thr Thr Thr
 100 105 110
- Gln Ala Pro Thr Thr Thr Gln Ala Pro Thr Thr Thr Thr Gln Ala
 115 120 125
- 50 Pro Thr Thr Thr Thr Gln Ala Pro Thr Thr Thr Gln Ala Pro Thr Thr
 130 135 140
- Thr Gln Ala Pro Thr Thr Thr Gln Ala Pro Thr Thr Thr Gln Ala
 145 150 155 160
- 55 Pro Thr Thr Thr Thr Gln Ala Pro Thr Thr Thr Thr Gln Ala Pro Thr
 165 170 175
- Thr Thr Gln Ala Pro Thr Thr Thr Gln Ala Pro Thr Thr Thr Gln Ala
 180 185 190
- 60 Pro Thr Thr Ile Thr Gln Ala Ala Thr Thr Pro Ala Ala Thr Thr Pro
 195 200 205

	Ala	Ala	Thr	Thr	Pro	Ala	Ala	Thr	Thr	Pro	Ala	Ala	Thr	Thr	Pro	Ala	
	210						215					220					
5	Ala	Thr	Thr	Pro	Gly	Val	Pro	Ala	Pro	Thr	Ser	Ala	Pro	Val	Trp	Pro	
	225				230						235					240	
	Pro	Ile	Cys	Glu	Leu	Leu	Pro	Asn	Gly	Cys	Pro	Ala	Asp	Phe	Asp	Ile	
					245					250					255		
10	His	Leu	Leu	Ile	Pro	His	Asp	Lys	Tyr	Cys	Asn	Leu	Phe	Tyr	Gln	Cys	
				260					265					270			
	Ser	Asn	Gly	Tyr	Thr	Phe	Glu	Gln	Arg	Cys	Pro	Glu	Gly	Leu	Tyr	Phe	
				275				280					285				
15	Asn	Pro	Tyr	Val	Gln	Arg	Cys	Asp	Ser	Pro	Ala	Asn	Val	Glu	Cys	Asp	
		290				295						300					
20	Gly	Glu	Ile	Ser	Pro	Ala	Pro	Pro	Val	Thr	Glu	Gly	Asn	Glu	Asp	Glu	
	305				310						315				320		
	Asp	Ile	Asp	Ile	Gly	Asp	Leu	Leu	Asp	Asn	Gly	Cys	Pro	Ala	Asn	Phe	
				325						330					335		
25	Glu	Ile	Asp	Trp	Leu	Leu	Pro	His	Gly	Asn	Arg	Cys	Asp	Lys	Tyr	Tyr	
				340					345					350			
	Gln	Cys	Val	His	Gly	Asn	Leu	Val	Glu	Arg	Arg	Cys	Gly	Ala	Gly	Thr	
				355				360					365				
30	His	Phe	Ser	Phe	Glu	Leu	Gln	Gln	Cys	Asp	His	Ile	Glu	Leu	Val	Gly	
		370				375						380					
35	Cys	Thr	Leu	Pro	Gly	Gly	Glu	Ser	Glu	Glu	Val	Asp	Val	Asp	Glu	Asp	
	385				390						395				400		
	Ala	Cys	Thr	Gly	Trp	Tyr	Cys	Pro	Thr	Glu	Pro	Ile	Glu	Trp	Glu	Pro	
				405						410					415		
40	Leu	Pro	Asn	Gly	Cys	Pro	Ala	Asp	Phe	Ser	Ile	Asp	His	Leu	Leu	Pro	
				420					425					430			
	His	Glu	Ser	Asp	Cys	Gly	Gln	Tyr	Leu	Gln	Cys	Val	His	Gly	Gln	Thr	
		435				440						445					
45	Ile	Ala	Arg	Pro	Cys	Pro	Gly	Asn	Leu	His	Phe	Ser	Pro	Ala	Thr	Gln	
	450					455						460					
50	Ser	Cys	Glu	Ser	Pro	Val	Thr	Ala	Gly	Cys	Gln	Val	Phe	Glu	Cys	Asp	
	465				470						475				480		
	Ser	Asp	Asn	Gln	Cys	Thr	Ser	Thr	Ala	Ala	Pro	Thr	Ala	Ala	Pro	Thr	
				485					490						495		
55	Ala	Ala	Pro	Thr	Ala	Ala	Pro	Thr	Ala	Ala	Pro	Thr	Ala	Ala	Pro	Ser	
			500					505						510			
	Thr	Val	Val	Pro	Pro	Ala	Thr	Pro	Pro	Ala	Thr	Ala	Ala	Pro	Val	Pro	
		515						520				525					
60	Pro	Thr	Thr	Ala	Ile	Pro	Thr	Pro	Ala	Pro	Thr	Ala	Ala	Pro	Thr	Ala	
		530				535						540					
	Ala	Pro	Thr	Thr	Ala	Ala	Pro	Glu	Ser	Pro	Thr	Thr	Val	Thr	Val	Pro	

	545		550		555		560
	Pro Thr Ala Ala	Pro Thr Ala Ala	Pro Thr Thr Ala Val	Pro Glu Ile			
		565	570	575			
5	Pro Ile Thr Val	Thr Ser Ala Pro	Thr Ala Ala Pro	Thr Ala Pro			
		580	585	590			
10	Thr Ala Ala Pro	Thr Thr Ala Val	Pro Glu Ile	Pro			
		595	600	605			
	Thr Thr Val Thr	Thr Ser Pro	Thr Thr Ala Ala	Thr Thr Ala Ala	Pro		
		610	615	620			
15	Ala Pro Asn Thr	Thr Val Thr Val	Pro Pro Thr	Ala Ala Pro	Thr Thr		
		625	630	635	640		
	Ala Ala Pro Ala	Pro Asn Thr	Thr Val Thr	Ala Pro	Pro Thr	Ala Ala	
		645	650	655			
20	Pro Thr Thr Ala	Ala Pro Ala	Pro Asn Thr	Thr Val Thr	Val Pro	Pro	
		660	665	670			
25	Thr Ala Ala Pro	Thr Thr Thr	Val Thr Val	Ala His	Ala Pro	Asn	
		675	680	685			
	Thr Thr Ala Ala	Pro Val Thr	Thr Thr Ser	Ala Pro	Ala Thr	Thr Pro	
		690	695	700			
30	Glu Asp Asp Asp	Ile Asp Pro	Pro Leu Pro	Asn Asp	Pro Ile	Asn Pro	
		705	710	715	720		
	Cys Val Glu Glu	Cys Asn Val	Leu Pro Trp	Ala His	Ala Asp	Cys Asp	
		725	730	735			
35	Lys Tyr Trp Val	Cys Asp Gly	Asn Asn Gln	Val Leu	Val Val	Cys Ser	
		740	745	750			
40	Glu Gly Leu Gln	Phe Asn Pro	Thr Thr Lys	Thr Cys	Asp Phe	Ala Cys	
		755	760	765			
	Asn Val Gly Cys	Val Arg Ser	Asn Ile Gln	Met Ser	Glu Ser	Tyr Glu	
		770	775	780			
45	Gly Val Gln Val	Phe Ile Pro	Trp Asn Lys	Leu Asp	Glu Asp	Ile Arg	
		785	790	795	800		
	Gln Ala Leu Asn	Phe Glu Leu					
		805					

What is claimed is:

- 1 1. A virus, microorganism, cell, plant, or animal, wherein said virus, microorganism,
2 cell, plant, or animal is the product of an insertion of a gene expression vector
3 including a DNA that encodes a IIM protein sequence into a host such that said
4 virus, microorganism, cell, plant, or animal is capable of expressing said IIM
5 protein in a functional form.
- 1 2. The microorganism of claim 1 wherein said host is *Escherichia coli*.
- 1 3. A recombinant DNA sequence comprising a DNA sequence that codes for an IIM
2 protein.
- 1 4. A recombinant DNA sequence of claim 3, wherein the nucleic acid sequence of said
2 recombinant DNA is selected from the group consisting of
3 a) a cDNA sequence as shown in SEQ. ID. No. 1; and
4 b) a cDNA sequence as shown in SEQ. ID. No. 2.
- 1 5. A recombinant DNA sequence of claim 3, wherein said IIM protein has an amino
2 acid sequence selected from the group consisting of:
3 a) an amino acid sequence as shown in SEQ. ID. No. 3; and
4 b) an amino acid sequence as shown in SEQ. ID. No. 4.
- 1 6. A method of producing a IIM protein or peptide comprising:
2 a) transforming a host cell with an expression vector comprising a
3 promoter operatively linked to a nucleotide sequence which
4 codes for a predetermined protein or peptide of a IIM protein;
5 b) culturing said host cell under conditions such that said IIM protein is
6 expressed in recoverable quantity;
7 c) lysing said host cell; and

8 d) recovering said IIM protein.

1 7. A gene expression vector containing a recombinant DNA sequence encoding a
2 *Trichoplusia ni* IIM protein sequence.

1 8. A expression vector of claim 7, wherein said expression vector is a recombinant
2 plasmid adapted for insertion into and transformation of bacteria.

1 9. The method of claim 6 wherein said transfer molecule is glutathione-S-transferase.

1 10. An expression vector of claim 7, wherein said expression vector is a recombinant
2 plasmid adapted for insertion into and transformation of a plant..

1 11. A fusion protein that includes a first protein linked to a second protein that
2 comprises at least a functional domain of a *Trichoplusia ni* IIM protein.

1 12. A substantially pure preparation of a IIM protein polypeptide.

1 13. A microorganism, cell, plant, or animal, wherein said microorganism, cell, plant, or
2 animal is the product of an insertion of a gene expression vector including a
3 DNA into a host, wherein said DNA encodes an antibody that binds to an IIM
4 protein sequence such that said microorganism, cell, plant, or animal is capable
5 of expressing said antibody directed against said IIM protein in a functional
6 form.

1 14. The microorganism, cell, plant, or animal of claim 13, wherein said antibody
2 specifically binds to a chitin binding region of said IIM protein.

1 15. An antibody produced by the microorganism, cell, plant, or animal of claim 13.

1 16. A purified and isolated antibody that specifically binds to an IIM protein.

1 17. The antibody of claim 16, wherein said antibody specifically binds to a chitin
2 binding region of said IIM protein.

1 18. A recombinant DNA molecule comprising a nucleotide sequence which codes for a
2 fusion protein that includes a first protein linked to a second protein that
3 comprises at least a functional chitin binding domain of a *Trichoplusia ni* IIM
4 protein.

1 19. A method of protecting a plant against an insect pest that includes an IIM protein in
2 said insect pest's midgut, comprising:

- 3 a) transforming a microorganism, cell, plant, or animal, wherein said
4 microorganism, cell, plant, or animal is the product of an
5 insertion of a gene expression vector including a DNA into a
6 host, wherein said DNA encodes an antibody that binds to an
7 IIM protein sequence such that said microorganism, cell, plant,
8 or animal is capable of expressing said antibody directed against
9 said IIM protein in a functional form; and
- 10 b) placing said transformed microorganism, cell, plant, or animal in an
11 environment that includes a plant to be protected and said insect
12 pest such that said insect pest is likely to come into contact with
13 said expressed antibody that binds to an IIM protein sequence.

ABSTRACT OF THE DISCLOSURE

The invention represents the disclosure of a novel insect intestinal mucin. The IIM protein was been identified and cloned using *T. ni* larva. The cDNA and amino acid sequences have been determined and are disclosed. The novel protein has an approximate molecular mass of 400 kDa. These sequences are useful for the production of transgenic or recombinant vectors including viral, microorganism, cell, plant, or animals, wherein the virus, microorganism, cell, plant, or animal is the product of an insertion of a gene expression vector including a DNA that encodes an IIM protein sequence. Thereafter the engineered host of the IIM DNA sequence is capable of expressing said IIM protein in a functional form. Also useful is a purified and isolated recombinant DNA sequence comprising a DNA sequence that codes for an IIM protein. The recombinant DNA sequence used can be a cDNA sequence for either IIM14 or IIM22, SEQ. ID.'s No. 1; and 2 respectively. The current invention also provides for the use of the purified amino acid sequences of IIM14 or IIM22, SEQ. ID.'s 3 or 4 respectively. With this knowledge of the proteinaceous components of the PM, and particularly the mucin-like proteins it will be possible to enhance the effectiveness of bio-engineered pesticides, recombinant viral vectors, enhance the defenses of transgenic plants, or protect insect vectors susceptible to attack by organisms utilizing enhancin or enhancin-like enzymes.




Figure 1

FIG. 2




FIG. 3




FIG.4

11 NP---ALNEPHPOCPA-EQHLLPHEVDCKFYVCEYGLKFIAPDCAPGTEFKFSAQICUHAALACIT---LPGPPA-E
 IUa ELLPNCCPADFOIHLIPADKYCHLFVOCNNGYTF--EORCPGELVFNPVUQACDPAKUECDGEISPAPPUTE
 IUb EDIDIG-DLLNGCPANFEIOHLLPHGNACDKYVOCNNGHLU--EAPCGAGTHFSFELQCCDHIELUGCIT-----LPGGES
 IUa PTEPIEHEPLNCCPADFSIDHLLPHESOCCKYLOCNHGGTI--RAPCPGNLHFSPTQSCESPATAGC-----UFE
 UI PNDPI-----HPCWEECHU--LPUAHACCKYVUCDGNHQLUU--CSEGLQFNPTTKTCDACHUGCN-----RSN

*

▲

▲